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ABSTRACT 
Background  
The spread of resistance to SP across Africa threatens the usefulness of intermittent 
preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-
SP) in West Africa. There is need for an alternative drug for IPTp or an alternative 
strategy for delivery of drug-based prevention of MiP. This trial, investigated, whether 
screening pregnant women for malaria using a rapid diagnostic test (RDT) at 
antenatal clinic and treating those with positive results with artemether-lumefantrine 
(Intermittent Screening and Treatment) is as effective and as safe as IPTp-SP. 
Methods 
Between October 2013 and November 2014, 460 pregnant women attending 
antenatal clinic in Calabar Southeast Nigeria were randomised to either IPTp-SP or 
intermittent screening and treatment with artemether-lumefantrine (ISTp-AL). All 
women received a long-lasting insecticide-treated net at enrolment. Study women 
had a maximum of four scheduled visits following enrolment. Haemoglobin 
concentration and peripheral parasitaemia were assessed in the third trimester (36-
40 weeks gestation). Birth weights were measured at delivery or within six days for 
babies delivered at home. In addition, the prevalence of molecular markers of 
resistance to SP among pregnant women was established. 
Results 
In the third trimester, the overall prevalence of severe anaemia (Hb<8 g/dl) and 
moderate anaemia (8 -10.9 g/dl) was 0.8% and 27.7% respectively and was similar 
in both groups (p=0.204). The risk of severe anaemia did not differ significantly 
between both groups (risk difference -1.75% [95% CI; -4.16 to 0.66]. The risk of 
parasitaemia was considerably lower in the ISTp-AL arm (risk difference -3.96% 
[95% CI -7.76 to -0.16]). The risk of low birthweight was significantly lower in the 
ISTp-AL arm after controlling for maternal age, gravidity and baseline parasitaemia 
(risk difference -1.53% [95% CI; -1.54 to -1.51]). Complaints of fever were more 
frequent in the ISTp-AL arm (p=0.022). The prevalence of the triple Pfdhfr mutation 
and the A437G/A581G mutations were very high among malaria positive women. 
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Conclusions 
The trial results suggest that in this area of high and perennial malaria transmission 
with moderate sulfadoxine-pyrimethamine resistance, ISTp with AL may be an 
effective strategy for controlling malaria in pregnancy. 
Keywords: malaria, sulfadoxine-pyrimethamine resistance, gametocytes, QT-
NASBA  
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1 INTRODUCTION, JUSTIFICATION AND OBJECTIVES OF 
THE STUDY 
1.1 INTRODUCTION 
Malaria in pregnancy remains a global health problem, accounting for 15% of 
maternal deaths in some malaria endemic regions (Menendez et al., 2008). Malaria 
also contributes to low birth weight (LBW), either through intrauterine growth 
retardation (IUGR) or preterm delivery. Malaria also contributes to the occurrence of 
severe maternal anaemia (Desai et al., 2007). An estimated 125 million women living 
in malaria-endemic areas become pregnant each year (Dellicour et al., 2010), and 
over half live in high-transmission areas in Africa (World Health Organization, 2011).  
The World Health Organization (WHO) recommends a package of interventions to 
prevent the adverse effects of malaria in pregnancy (MiP) in areas with stable 
transmission in sub-Saharan Africa. The package of interventions includes the use of 
insecticide-treated nets (ITN), intermittent preventive treatment with sulphadoxine-
pyrimethamine (IPTp-SP) and effective case management of malaria and anaemia 
(World Health Organization, 2004). IPTp-SP is delivered to pregnant women 
primarily through antenatal care (ANC) clinics, and ITNs are delivered through ANC 
together with other systems and mechanisms. Since 2012, revised WHO guidelines 
now recommend a dose of IPTp-SP at each scheduled ANC visit, beginning as early 
in the second trimester, and with each dose at least a month apart with each woman 
receiving at least three doses of IPTp-SP during each pregnancy.This 
recommendation is for pregnant women living in areas of moderate-to-high malaria 
transmission (World Health Organization, 2012a). 
IPTp-SP has been shown to be effective in preventing maternal and placental 
malaria as well as improving pregnancy outcomes among parturient women in 
Nigeria (Falade et al., 2007, Aziken et al., 2011, Agomo et al., 2011). SP has 
remained the drug of choice for IPTp because of its efficacy, convenient treatment 
dose, and high compliance rate. However, the emergence and increasing spread of 
Plasmodium falciparum parasites resistant to SP have raised concern over the long-
term usefulness of SP as IPTp (Iriemenam et al., 2012, Mockenhaupt et al., 2008). 
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1.2 JUSTIFICATION OF THE STUDY 
There has been a global decline in the number of malaria cases globally including 
Africa but the delirious effects of malaria in pregnancy remain a key public health 
problem in Nigeria. SP remains the drug of choice for IPTp despite growing 
resistance. It may be useful only to administer full malaria treatment doses to 
pregnant women only when parasitaemia is detected as a mechanism for reducing 
drug pressure and resistance. It has been argued that the continued use of SP for 
intermittent preventive treatment in pregnant women, may further increase the 
prevalence of SP-resistant parasites and/or lead to the selection of new mutations 
(Lucchi et al., 2015). 
Studies have proposed that Intermittent Screening and Treatment (IST) - screening 
of pregnant mothers using rapid diagnostic test (RDT) for malaria infection at 
scheduled antenatal clinic visits may be a good alternative to IPTp-SP. With this 
approach, treatment with an effective antimalarial is given only to women with 
parasitologically confirmed malaria. (Tagbor et al., 2010, Tagbor et al., 2015).  In 
Nigeria, artemether-lumefantrine (AL) is the first-line treatment for uncomplicated 
falciparum malaria in adults and children and is safe for use in pregnancy in the 
second and third trimesters (Federal Ministry of Health, 2011). 
This study was designed to compare the effectiveness of intermittent screening and 
treatment with artemether-lumefantrine (ISTp-AL) to intermittent preventive treatment 
with SP (IPTp-SP) in pregnant women in Calabar, Cross River State, south-east 
Nigeria; an area of high perennial malaria transmission and widespread SP 
resistance in the general population (Federal Ministry of Health, 2002). 
1.3 OBJECTIVES OF THE STUDY 
1.3.1 BROAD OBJECTIVE 
To show that the long-lasting insecticidal net (LLIN) plus parasitological screening 
followed by treatment with AL (ISTp-AL) is not inferior to LLIN plus IPTp-SP in 
reducing the burden of malaria during pregnancy. 
1.3.2 SPECIFIC OBJECTIVES 
Primary objective 
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1. To compare the prevalence of severe anaemia (Hb < 8g/dl) at 36 to 40 weeks 
of gestation in the ISTp and IPTp arm. 
  
Secondary objectives 
2. To compare the prevalence of LBW (BW < 2500g) within 4 -6 days of birth in 
the ISTp and IPTp arm. 
 
3. To compare the prevalence of anaemia (Hb < 11g/dl) at 36 to 40 weeks of 
gestation in the ISTp and IPTp arm. 
 
4. To determine the prevalence of SP molecular resistance markers in P. 
falciparum isolates from pregnant women in Southeast, Nigeria 
 
5. To compare prevalence and density of maternal parasitaemia at each visit in 
the ISTp and IPTp arm 
  
6. To compare the incidence of spontaneous abortions, intrauterine 
deaths/stillbirths, neonatal and maternal mortality and developmental delays 
in the ISTp and IPTp arm. 
 
7. To compare prevalence and density of gametocytaemia at each visit in the 
ISTp and IPTp arm. 
 
8. To compare the prevalence of placental malaria at delivery in the ISTp and 
IPTp arm. 
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2 LITERATURE REVIEW 
2.1 MALARIA BIOLOGY  
Malaria is a febrile illness caused by protozoan parasites of the genus Plasmodium. 
Infected female anopheline mosquitoes bite humans and transmit the parasite. Five 
species of Plasmodium cause malaria disease in humans: P. falciparum, 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and more recently 
Plasmodium knowlesi. P. ovale is made up of two subspecies P. ovale curtisi and P. 
ovale wallikeri. Plasmodium falciparum is the most common species globally, 
accounts for about 90% of malaria infections in Nigeria and is responsible for almost 
all of the severe disease and malaria deaths. The life cycle of P. falciparum consists 
of development in the human host and the mosquito vector (Figure 2.1). 
2.1.1 LIFE CYCLE OF THE MALARIA PARASITE – PLASMODIUM FALCIPARUM 
The life cycle of Plasmodium falciparum begins with the bite of an infected female 
Anopheles mosquito. The mosquito while taking a blood meal, releases sporozoites 
into the bloodstream which travel to the liver and invade the liver cells within 30 
minutes of the release. Inside the hepatic cells of the liver, the parasites rapidly 
differentiate and undergo asexual multiplication, resulting in the release of 
merozoites that invade other liver cells. The liver stage of P. falciparum life cycle 
lasts for 5 to 7 days and is not associated with any clinical manifestations. The liver 
stages of P. vivax, P.ovale and P. malariae last for 6-8 days, 9 days and 14-16 days 
respectively. 
These merozoites from the hepatocytes burst into the host’s bloodstream where they 
invade the erythrocytes. Further multiplication takes place inside the erythrocytes, 
enlarging into ring trophozoites that divide asexually producing schizonts. The 
schizonts divide further causing a release of merozoites when the erythrocytes are 
ruptured. The released merozoites in the blood stream are responsible for the clinical 
manifestation of malaria illness such as fever, joint and muscle pains and chills. This 
stage called the erythrocytic stage is the asexual life cycle of the parasite and usually 
lasts for 48 hours for P. falciparum. 
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Some of the schizonts divide into sexual forms resulting in male and female 
gametocytes. The female Anopheles mosquito takes up the gametocytes during 
another blood meal from a host. The male gametocytes undergo a rapid nuclear 
division inside the midgut of the mosquito resulting to microgametes, which fertilise 
the female macrogametes producing ookinete. The ookinete later crosses the gut 
wall as oocyst, which subsequently ruptures releasing sporozoites into the 
mosquito’s body cavity from where they eventually migrate to the salivary gland of 
the mosquito. With another blood meal, the mosquito transmits the sporozoites from 
its salivary glands into the human blood stream. (Centers for Disease Control and 
Prevention). 
 
Figure 2.1: Life cycle of malaria.  
Source: (Centers for Disease Control and Prevention)  
During malaria infection, both asexual and sexual forms of the parasite can circulate 
in the bloodstream. The proliferation of asexual forms in the host’s red blood cells 
causes clinical disease. The gametocytes do not directly cause disease symptoms 
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but are essential for transmission of the disease and spread of parasites in the 
population (Shute and Maryon, 1951) 
2.1.2 PLASMODIUM FALCIPARUM GAMETOCYTE DEVELOPMENT 
The developmental process of P. falciparum gametocytes to maturation involves five 
distinct stages (I-V) which occur over 10-12 days (Hawking et al., 1971). Although all 
five stages can be seen in in vitro parasite cultures, only stage V gametocytes can 
be viewed in the circulation because the immature stages (I-IV) sequester from the 
bloodstream. Stage I gametocytes cannot be distinguished from asexual 
trophozoites; because morphological changes begin from the Stage II and 
morphological differences between male and female gametocytes are clearly visible 
from Stage III gametocytes (Sinden, 1982). 
In stage III, gametocytes lengthen further, and the ends become rounded. In 
females, mitochondria and Golgi bodies proliferate. Stage IV gametocytes continue 
to lengthen but now have pointed ends, and osmiophilic bodies and extensive rough 
endoplasmic reticulum develop in females. Gametocytes eventually assume their 
characteristically crescent shape in stage V. In this stage, male and female 
gametocytes can be readily differentiated, as the females are more elongated and 
curved than the thicker males (Dixon et al., 2012). 
Stages I to III are susceptible to schizonticidal antimalarials. For Stages IV and V, 
which represent the last part of their maturation process, they become generally 
insensitive to most antimalarial drugs, except for primaquine and methylene blue 
(Adjalley et al., 2011, Smalley, 1977, Chutmongkonkul et al., 1992, Kumar and 
Zheng, 1990, Burgess and Bray, 1961). Mature stage V gametocytes are 
developmentally arrested, and current evidence suggests that they are minimally 
metabolically active (Sinden and Smalley, 1979). This reduced metabolism may 
account for their insensitivity to most schizonticidal drugs (Smalley, 1977, 
Chutmongkonkul et al., 1992). 
Several stage-specific molecular and biochemical changes precede the 
morphological changes of the gametocyte (Schneider et al., 2004). Sexual stage 
development begins in the asexual cycle prior to morphological changes of the 
gametocytes with the expression of Pfs16 mRNA as the initial marker of parasite 
commitment to sexual stage development (Bruce et al., 1990, Niederwieser et al., 
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2000). Schizonts that are committed to developing into sexual stage parasites then 
produce only one sex of gametocytes (all either male or female gametocytes) 
(Silvestrini et al., 2000, Smith et al., 2000). 
2.2 MOLECULAR DETECTION OF PLASMODIUM FALCIPARUM 
Molecular techniques for P. falciparum detection are based on DNA or RNA 
amplification and are more sensitive than light microscopy. However, these 
molecular techniques have their limitations. Problems are often encountered with 
either stage-specific detection or quantification. Polymerase chain reaction (PCR) 
can detect parasite DNA with a detection limit of about 20 parasites/ml of blood 
(Snounou et al., 1993, Rubio et al., 2002) however, it is semi-quantitative and thus 
does not accurately quantify the number of parasites present. Quantitative real-time 
PCR (Real-time Q-PCR) was developed for detection of P. falciparum 18S small 
subunit ribosomal RNA genes and can detect up to 20 parasites/ml of blood 
(Hermsen et al., 2001). The technique, however, requires relatively large amounts of 
venous blood (up   to 0.5 ml), and white blood cells need to be filtered from the blood 
samples to prevent problems during processing, caused by otherwise gelatinous 
DNA preparation (Hermsen et al., 2001). Additionally, PCR techniques based on the 
amplification of DNA cannot detect several developmental stages of the parasites, 
including gametocytes. With reverse- transcriptase PCR (RT-PCR) detection of the 
various developmental stages in quantitative and sensitive assays based on stage-
specific gene expression is possible (Babiker et al., 1999). However, because introns 
are absent in most Plasmodium genes, this method cannot definitively detect RNA 
without the complete removal of genomic DNA from the sample. Even a DNase 
treatment of the isolated RNA often does not ensure absolute removal of genomic 
DNA. This affects accurate quantification using RT-PCR (Schneider, 2006). One 
technique that may avoid the above-stated problems is quantitative nucleic acid 
sequence-based amplification (QT-NASBA). 
2.3 MOLECULAR QUANTIFICATION OF GAMETOCYTES 
Due to sequestration in the vasculature, only asexual ring stages, sexually 
committed ring stages, and mature gametocytes of P. falciparum can be found in the 
circulation (Schneider et al., 2004). The differential expression of the sexual stage-
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specific genes Pfs16 and Pfs25 allows for separate quantification of these stages 
(Figure 2.2). Pfs16 mRNA expression aids in the identification of circulating sexual 
stage parasites i.e. sexually-committed ring stages and fully mature gametocytes. 
However, Pfs25 mRNA is expressed only in Stage V gametocytes, which means it 
can be used as a marker to quantify mature gametocytes specifically (Babiker et al., 
1999). Recent findings suggest that it is possible to differentiate female from male 
gametocytes by RNA. It has been established that Pfs25 and Pfs230p mRNA 
expression is specific to mature female and male gametocytes respectively 
(Schneider et al., 2015). 
 
 
Figure 2.2: Differential expression of the sexual stage-specific genes Pfs16 and 
Pfs25.  
Neg: negative, no RNA expression; pos: positive, RNA expression.  
Source: (Schneider et al., 2004). 
2.4 QUANTITATIVE NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (QT- 
NASBA) 
QT-NASBA employs the activities of three enzymes (AMV-RT, RNase H, and T7 
RNA polymerase). It also involves two target-specific primers, of which one includes 
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a T7 polymerase promoter, for continuous and direct amplification of RNA molecules 
in a single mixture at a temperature of 41oC (Compton, 1991, Van Gemen et al., 
1993, Schneider et al., 2004). The low-temperature guarantees that primers only 
anneal to single-stranded target RNA and prevents the amplification of genomic DNA 
which may be present in the sample. This low-temperature allows for specific 
detection of living, metabolically active cells and organisms. Figure 2.3 shows a 
schema of the principle of QT-NASBA. Detection of the amplified nucleic acid during 
the amplification reaction results in the real-time detection of positive signal, thus 
minimising the hands-on time compared to detection methods that need post-
amplification handling of the amplified nucleic acid. The various developmental 
stages of the same organism can be detected by QT-NASBA through the 
measurement of stage-specific gene expression. This can be performed on small 
finger-prick blood samples. The high accuracy, sensitivity and quick reaction times 
that allow for high throughput of samples, make QT-NASBA extremely suitable for 
large-scale epidemiological investigations.  
QT-NASBA has proved to be more sensitive and specific than other available 
molecular techniques, especially for RNA targets (Deiman et al., 2002). QT-NASBA 
for the detection of P. falciparum parasite loads has a detection limit of about 10 
parasites/ml of blood (Schoone et al., 2000, Smits et al., 1997). This technique is 
based on specific amplification of 18S rRNA of the parasites and detection using 
electrochemiluminescence (ECL). Due to the ability of QT-NASBA to accurately 
quantify RNA in the presence of DNA, it can be used to detect various parasite 
developmental stages based on their stage-specific differences in gene expression. 
For P. falciparum, this may enable separate quantification of gametocytes in the 
blood sample (Schneider et al., 2004). 
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Figure 2.3: Principle of nucleic acid sequence-based amplification.  
Source: (Premier Biosoft, 2016)  
This mechanism requires two short single-stranded DNA fragments, primers, and 
three enzymes. The viral RNA strands are represented as the sense strand present 
in the original samples. Primer P1 binds to the RNA and is elongated by reverse 
transcriptase (AMV-RT). The RNA strand of the yielded DNA: RNA hybrid is 
hydrolyzed by RNase H. After the binding of P1, primer P2 can also bind. AMV then 
elongates primer P2 – RT, yielding a double-stranded DNA molecule. Primer P1 is 
designed in such a manner that when it forms a double- stranded DNA, it codes for a 
T7 RNA polymerase Promoter site. This helps in generating antisense RNA copies 
using a DNA template. The new copies of DNA are generated using RNA. The 
process is same as followed for sense strand. Here, in this case, P2 will bind first. In 
a NASBA reaction, DNA is the final product formed. It has a promoter region. This 
allows T7 RNA polymerase to use it as a template. The reaction sequences starting 
from the sense and antisense RNA strands are different, but they are considered 
kinetically identical. They both are referred to as copy DNA (cDNA). 
 
2.5 MALARIA TRANSMISSION AND ENDEMICITY 
The pattern of malaria transmission underpins several aspects of malaria 
epidemiology. It affects the prevalence, age profile of infection, the incidence and 
types of syndromes as well as mortality. Knowledge of all these characteristics 
influences the choice of appropriate interventions to be used in malaria control and 
also affect the outcome of control efforts (Hay and Snow, 2006, Hay et al., 2008). 
The intensity of malaria transmission is dependent on factors related to the 
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environment, the vector, the parasite, and the human host. The level of malaria 
endemicity varies between different geographical areas and between and within 
countries. 
Transmission is intense in places where the mosquitoes are anthropophilic and 
where favourable climatic conditions (temperature, humidity and rainfall patterns) 
prolongs the lifespan of the mosquitoes and increases abundance. This ensures 
parasites have ample time to complete their development inside the mosquito. These 
two attributes of the dominant African vector species-Anopheles gambiae is the 
principal reason why close to 90% of global malaria cases are in Africa (World 
Health Organization, 2015a).  
In areas of stable transmission, there is often an increased incidence coinciding with 
increased mosquito breeding during the rainy season. In such areas, morbidity, and 
mortality from malaria are marked during early childhood, but by adulthood most 
malaria infections are asymptomatic (Dondorp et al., 2008).   
In other settings, transmission is seasonal, with the peak during and immediately 
after the wet season. Malaria epidemics can occur when climatic factors and other 
conditions unexpectedly become favourable for transmission in areas where the 
population have little or no malaria immunity. They can also happen when people 
with low immunity move into areas with intense malaria transmission, for instance, to 
find work, or when displaced by conflict (White et al., 2014) 
Human immunity is another important factor, especially among adults in areas of 
moderate or intense transmission conditions. Partial immunity develops over years of 
exposure, and while it never provides complete protection, it does reduce the risk of 
severe disease. Thus, most malaria deaths in Africa occur in young children under 
five years of age, whereas in areas with less malaria transmission and low immunity, 
all age groups are at risk (World Health Organization, 2014a). 
2.6 MALARIA IN SUB-SAHARAN AFRICA 
Malaria continues to be a threat for the sub-Saharan Africa population. The past 
century has witnessed lots of research in malaria after the discovery of malaria 
parasites in human blood by Charles Laveran in 1880 (Raghavendra et al., 2011) 
and the establishment of the mosquito’s role in the transmission of malaria by Sir 
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Ronald Ross in 1898. There were 214 million (95% confidence interval 149-303) 
cases of clinical malaria in 2015 of whom 88% or 188 million cases occurred in the 
African region. Approximately 438 000 malaria deaths occurred in 2015 of which 
90% or 395 000 were in the African region; deaths in children less than five years old 
accounted for 74% of the estimated deaths (World Health Organization, 2015a). A 
concerted global effort, through renewed political will and social support, has been 
made in the last 15 years to reduce the high burden of malaria in the world and 
mainly in sub-Saharan Africa. Different approaches have been proposed to combat 
malaria. It has been postulated that malaria could only be surmounted through 
improved access to diagnosis and treatment, coupled with health system 
strengthening, human capacity building, environmental management, and economic 
development. Others favoured a more aggressive approach using large-scale formal 
campaigns of vector control or mass drug administration to quickly prevent and 
eradicate malaria from the world.   
The latter approach achieved remarkable feats such as the interruption of malaria 
and yellow fever transmission during the construction of the Panama Canal and the 
elimination of the African vector An. gambiae in Brazil. However, sustainability 
seemed to require the solid public health foundations envisaged by the former 
approach (Nájera et al., 2011). 
 
2.7 HISTORICAL MALARIA ERADICATION PROGRAMMES: SUCCESS AND FAILURE 
Eradication refers to the permanent reduction to zero of the global incidence of 
malaria as a result of deliberate efforts. Eradication would mean intervention 
measures are no longer needed. In the context of malaria, this would entail the 
extermination of the parasite, not the mosquitoes that transmit malaria (Roll Back 
Malaria, 2014).  
Malaria was eliminated from most of Europe and the United States during the first 
half of the twentieth century as a result of changes in land use, agricultural practices 
and house construction and some targeted vector control (Greenwood and 
Mutabingwa, 2002). The discovery of the insecticidal activity of 
DichloroDiphenylTrichloroethane (DDT) in 1939 by Paul Müller initiated a global 
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programme for the elimination of malaria in the 1950s and sixties (Centers for 
Disease Control and Prevention, 2016). 
DDT was used by many national malaria control programmes for indoor residual 
spraying (IRS) in the malaria eradication programme from 1957 to 1969. The World 
Health Organization (WHO) eradication efforts focused on house spraying with 
residual insecticides, mass drug administration (MDA), and surveillance. It was to be 
carried out in four successive steps: preparation, attack, consolidation, and 
maintenance (World Health Organization, 2006a).   
MDA is the administration of a full therapeutic dose of an antimalarial regimen to an 
entire population or well-defined subpopulation at the same time. The strategy was 
recommended by the World Health Organization in the 1950’s as an extra tool to 
replace failing strategies (von Seidlein et al., 2003). MDA works through the 
reduction of the prevalence of peripheral parasitaemia and the reduction of 
transmission by the inhibition of the liver or asexual intraerythrocytic stages of the 
parasite, the direct action on the gametocytes or a sporonticidal effect and the 
inhibition of the sporogonic cycle in the mosquitoes (Poirot et al., 2013). 
As a result of IRS the total population at risk was halved by 1975, from 77% in 1900 
and there was a dramatic decrease in the mortality rate from 19.4 per 10 000 in 1900 
to 1.61 per 10 000 in 1975 (Enayati and Hemingway, 2010). Achievements included 
elimination in nations with temperate climates and seasonal malaria transmission. 
This strategy was initially very successful in eliminating malaria in countries with 
temperate climates and seasonal malaria transmission such as India, Sri Lanka and 
the former Soviet Union (Greenwood and Mutabingwa, 2002).  However, this 
success was not sustained, as highlighted by substantial increases in the incidence 
of malaria, due to the high costs of the programme, the resistance of many 
communities to repeated spraying of their homes and the emergence of vector 
resistance to DDT(Greenwood and Mutabingwa, 2002). The failure of this global 
strategy coupled with the magnitude and intensity of malaria transmission meant that 
malaria eradication was never systematically attempted in sub-Saharan Africa. 
However, control interventions before 1960 resulted in some countries in Southern 
Africa (South Africa, Swaziland, Zimbabwe, and Mauritius) reaching consolidation 
phase (stage 2 of the WHO elimination plan). There was also a trend towards the 
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interruption of transmission in forest areas of Liberia and Cameroon and highland 
savanna areas in Madagascar and Uganda (Enayati and Hemingway, 2010). 
Subsequently, pilot interventions were conducted in five eco-epidemiological zones 
of Africa to ascertain whether malaria transmission could be interrupted on a local 
scale (Molineaux et al., 1980). These pilot interventions recorded significant success 
in areas of Africa with tropical and temperate climates (semi-desert areas, remote 
islands, and Highland savannahs) where malaria was eliminated. There were also 
drastic reductions in transmission intensity in hyperendemic areas (Bradley, 1991, 
Delfini, 1969) with the disappearance of the vector Anopheles funestus and declined 
density of An. gambiae (Enayati and Hemingway, 2010). Despite their impressive 
health benefits, the African trials were considered failures because elimination was 
not achieved (Lines et al., 2007). Few years after the interventions stopped, 
entomological indices had returned to pre-intervention levels (Enayati and 
Hemingway, 2010). 
MDA was used in conjunction with other control measures and proved to be 
successful in some settings. High propoxur IRS coverage was supplemented with 
MDA using sulfalene-pyrimethamine in the Garki project, Northern Nigeria 
(Molineaux et al., 1980). Notably, this combination of MDA and IRS also failed to 
interrupt transmission. 
MDA was a component of several malaria elimination programmes during the 
eradication era, but it is not currently recommended due to concerns about efficacy, 
logistical feasibility, sustainability and the promotion of drug resistance (Watkins et 
al., 1987). Though not officially endorsed by WHO, MDA is being considered and 
evaluated as an approach to reduce the burden of malaria with the ultimate goal of 
elimination. 
The development of intermittent preventive treatment was a way to build on 
limitations of MDA. With IPT, drug administration is repeated at intervals due to the 
short-lasting benefit of MDA (Zongo, 2014). 
2.8 MODERN MALARIA ELIMINATION AND ERADICATION 
The Roll Back Malaria (RBM) programme was established in 1998 with the major 
aim of halving the malaria burden by 2010 (Roll Back Malaria, 2005). Subsequently, 
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44 Heads of State and government delegations in April 2000, adopted the Abuja 
Declaration on Roll Back Malaria. They agreed the objective was to ensure that 60% 
of pregnant women and children under five years of age, who were vulnerable and 
susceptible, had access to ITNs and prompt, effective treatment of malaria by the 
year 2005 (Roll Back Malaria and World Health Organization, 2000). Since then, 
countries have made efforts to support the international fight to control malaria 
through the Roll Back Malaria initiative. The Partnership has grown over time with a 
wide array of organisations from country level to regional and global level.  
The goal of eradicating malaria was supported more ambitiously by the Bill & 
Melinda Gates Foundation (BMGF) in 2007 and supported by the WHO (Lines et al., 
2007, Feachem and Sabot, 2008). They acknowledged that the current tools were 
insufficient to bring about eradication. They identified new priorities such as 
transmission-blocking, chemoprotection in vulnerable groups, (malERA Consultative 
Group on Drugs, 2011) and new target candidate profiles (Alonso et al., 2011). They 
called for a massive directed research effort to produce a malaria vaccine, and better 
drugs and insecticides, together with a clear strategy for delivery to provide access 
to these new technologies in the poorest of the populations in malaria-endemic 
countries with the highest burden of disease. 
 
Figure 2.4: Classification of countries by stage of malaria elimination (December 
2014).  
Source: Global Malaria mapper (http://www.worldmalariareport.org/). 
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Significant and widespread reductions in malaria prevalence and incidence have 
occurred across Africa since 2000, as a result of sustained financing and scale-up of 
malaria control interventions. Between 2005 and 2015, there has been a 50% 
reduction in childhood malaria. Mortality and cases have reduced by 50% and 25% 
respectively. In this period, four countries have been certified as malaria-free by 
WHO (World Health Organization, 2014b). Figure 2.4 shows global progress made in 
efforts at eliminating malaria. The progress made has prompted increased global 
dialogue on malaria elimination and eradication. However, the decline remains below 
internationally agreed targets for universal coverage (World Health Organization, 
2015a). Insecticide-treated nets (ITNs) have had the greatest impact but have also 
been present for longer and at higher levels of coverage. Indoor residual spraying 
(IRS) and artemisinin combination therapy (ACTs) have both made substantial 
contributions to reducing prevalence and incidence where they have been 
implemented at scale (Bhatt et al., 2015a).  
There is an arsenal of novel promising tools to detect, treat and prevent malaria 
which are at different stages of research and development (Hemingway et al., 2016). 
Experts suggest that by 2035, with sustained commitment, funding for the universal 
coverage of existing tools and rapid scale-up and uptake of these new tools, the 
economic benefits from preventable malaria deaths would surpass the costs 
invested in malaria control interventions by a factor of up to 20 (Jamison et al., 2013)  
International development partners and public health experts seem to have 
embraced the goal of a “world free of malaria”. This is evident from the WHO’s 
Global Technical Strategy for Malaria (GTS), which was endorsed by the World 
Health Assembly in 2015, and the Action and Investment to defeat Malaria (AIM) 
document of the RBM Partnership which both allude to  the need to achieve a “world 
free of malaria”. Both documents have put forward ambitious targets of reducing 
malaria case incidence and mortality rates globally by at least 90% by 2030 (Roll 
Back Malaria Action, 2015, World Health Organization, 2015b). However, challenges 
remain in achieving these targets. Vector and parasite resistance to insecticides and 
medicines respectively continues to increase. Resistance to ACTs has been 
identified in Cambodia, Lao DPR, Myanmar, Thailand and Vietnam all in Southeast 
Asia. The spread of these strains to the Indian subcontinent or Africa could be 
disastrous. Furthermore, resistance has been detected against two or more 
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insecticides in two-thirds of African malaria-endemic countries (Hemingway et al., 
2016). 
2.9 GLOBAL MALARIA CONTROL 
Global malaria control programmes have three main components; vector control, 
chemoprevention and case management. Vector control aims to prevent 
transmission of the parasite from humans to mosquitoes and back to humans. 
Chemoprevention prevents new cases and suppresses blood-stage infection from 
further development to a clinical case. Finally, case management through prompt 
diagnosis and treatment if infectious contact happens and results in a clinical case. 
2.9.1 VECTOR CONTROL 
Vector control is an integral part of the strategies to prevent and reduce the malaria 
burden in endemic countries, by reducing transmission. It has been endorsed by 
WHO and the RBM partnership. ITNs or LLINs and indoor residual spraying (IRS) 
are currently the preferred methods of malaria vector control. In many malaria-
endemic countries, both approaches are used simultaneously in the same 
households to suppress transmission in hyper- and holoendemic situations (Okumu 
et al., 2011).  
Insecticide-treated bed nets 
LLINs reduce the number of malaria cases and deaths and represent a cornerstone 
of the scale-up in malaria control (World Health Organization, 2015a). The 
effectiveness of ITNs at preventing malaria morbidity and mortality has been 
demonstrated from the 1990s (Lengeler, 2000). Their public health impact has been 
proven, especially for ITNs which, in areas with high coverage rates, can reduce 
malaria cases by 40–60% (Roll Back Malaria, 2008). In Sub-Saharan Africa, less 
than one-third (29%) of households had enough ITNs for all household members, 
and one-third of households did not own a single ITN (World Health Organization, 
2014a). 
The Roll Back Malaria Partnership set goal was to scale-up ITN use to all pregnant 
women by 2015 (Roll Back Malaria, 2011). This target, however, was not met. 
Despite their proven efficacy, the achievement of widespread use of ITNs and LLINs 
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has been difficult because of sociologic or financial barriers or insufficiency of the 
provision.  
ITNs are bed nets that have been treated with safe, residual insecticide for the 
purpose of killing and repelling mosquitoes, which carry malaria (Curtis et al., 1996, 
Lines, 1996). LLINs are designed to remain effective for several years without 
retreatment. However, emerging resistance to pyrethroids, the only class of 
insecticides used in LLINs, is one of the key challenges for this tool. Also, replacing 
worn-out nets is crucial to achieving and maintaining universal coverage (Alonso and 
Tanner, 2013). Newer classes of insecticides which are longer-lasting are the current 
focus of research and development efforts. 
Considerable effort has been made to make the LLINs available to those who need 
them. This effort has focused mainly on the free distribution of LLINs to pregnant 
women and children less than five years old during antenatal care and the Expanded 
Programme on Immunisation (EPI) vaccination respectively. There have also been 
massive campaigns of LLIN distribution to households free of charge by National 
Malaria Control Programmes (NMCPs). LLINs are also provided through the private 
sector and non-governmental organisation usually at a subsidised price. Figure 2.5 
compares ITN coverage in 2000 to 2015 in sub-Saharan Africa. 
 
Figure 2.5: Proportion of population sleeping under an ITN, sub-Saharan Africa, 
2000 and 2015.  
Source: (Bhatt et al., 2015b). 
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Indoor residual spraying 
IRS is the application of stable formulations of insecticides to the inside of houses to 
kill resting adult female mosquitoes (Enayati and Hemingway, 2010). The primary 
contributions of IRS in reducing malaria transmission are shortening the life span of 
female mosquitoes so that they no longer transmit malaria parasites, and reducing 
the vector density. Current IRS insecticides last from two to six months. IRS is used 
in most malaria endemic countries although it protects only a small proportion of the 
at-risk population. Although, as many as 88 countries (42 in the WHO African region) 
have adopted IRS for vector control (World Health Organization, 2014b), coverage of 
IRS is significantly lower than that of ITNs. In 2014, only 3.4% of the global 
population at risk was protected by IRS, decreasing from more than 5% in 2010 
(World Health Organization, 2015a). Spraying at least 80% (ideally 100%) of houses, 
structures, and units in the target area in any round of spraying is recommended by 
WHO (World Health Organization, 2006b). 
In addition to huge gaps in coverage, the effectiveness of vector control is 
threatened as malaria mosquitoes develop resistance to the classes of insecticides 
used in ITNs and IRS. In some areas, resistance to all four classes of insecticides 
used for public health has been detected (see Table 2.1). The Global plan for 
insecticide resistance management in malaria vectors (World Health Organization, 
2012b) was launched by WHO to address this issue. It recommends strategies such 
as rotating insecticides and mosaic spreading to preserve the effectiveness of 
current compounds, and country implementation has started.  
The threat of insecticide resistance represents one of the main challenges to future 
progress against malaria; new products and chemical compounds to fight resistance 
are therefore a top priority for research and development. 
Other innovative vector control strategies include larval control measures and the 
development of transgenic mosquitoes.  
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Table 2.1: Insecticide resistance mechanisms of selected major malaria vector species.  
Source: (World Health Organisation, 2012b). 
Vector species Pyrethroids DDT Organophosphates Carbamates 
 Target-site Metabolic Target-site Metabolic Target-site Metabolic Target-site Metabolic 
An. gambiae s.s × × × × ×  × × 
An. funestus s.s    ×    × 
An. arabiensis ×  × × ×  ×  
An. culicifacies (C) ×  ×      
An. culicifacies (B) ×  × ×  ×   
An. stephensi × × × ×  ×   
An. dirus    ×     
An. sacharovi    × × × × × 
An. albimanus  ×  × × × ×  
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2.9.2 CASE MANAGEMENT 
Successful malaria control depends greatly on the prompt diagnosis and treatment of 
patients with efficacious antimalarial drugs. The WHO Global Malaria Programme’s 
initiative – T3 (Test. Treat. Track.) - supports malaria-endemic countries to achieve 
universal coverage with diagnostic testing and antimalarial treatment, as well as 
strengthen their malaria surveillance systems (World Health Organization, 2012c). 
Malaria-endemic countries are expected to ensure that all suspected malaria cases 
are tested and that every confirmed case is treated with quality-assured antimalarial 
medicine. Also, it is important that malaria disease is tracked through timely and 
accurate surveillance systems to guide policy and operational decisions (World 
Health Organization, 2012c).   
For decades chloroquine (CQ) was the mainstay of malaria chemotherapy and 
prevention because it was easy to use and well accepted despite the bitter taste of 
the tablets. However, resistant strains which appeared spread quickly rendering CQ 
no longer effective to treat malaria (Ezedinachi, 1996, Sirima et al., 2003, Tinto et al., 
2002).  
Amodiaquine was considered as a replacement for CQ but was more poorly 
tolerated than CQ. Sulfadoxine-pyrimethamine replaced CQ as the treatment for 
uncomplicated falciparum malaria. However, routine use as monotherapy 
accelerated the spread of SP resistance. Today its use is restricted to 
chemoprevention in infants, children, and pregnant women. In the face of the failing 
drugs, the idea of combination therapy emerged and was advocated for by WHO 
(Attaran et al., 2004). 
Today, countries have National Malaria Treatment Policies (NMTP), which specify 
drugs for the treatment of both uncomplicated and severe malaria, malaria in 
pregnancy as well as actions to be taken if first line treatment fails. 
Currently, artemisinin-based combination therapies (ACTs) are used worldwide as 
the first line of treatment for uncomplicated P. falciparum malaria (Bosman and 
Mendis, 2007). The use of two or more drugs with different modes of action in 
combination is the current recommendation. This is to provide adequate cure rate 
and delay the development of resistance. Fast acting artemisinin-based compounds 
such as dihydroartemisinin (DHA), artesunate (AS) and artemether, are combined 
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with a drug from a different class. Partner drugs include lumefantrine, amodiaquine 
(AQ), mefloquine (MQ) sulfadoxine-pyrimethamine (SP), piperaquine (PQ) and 
chlorproguanil-dapsone (CD).  
Currently, the management of clinical malaria is based on one of the five WHO 
recommended artemisinin combinations: Artemether-Lumefantrine, Artesunate-
Amodiaquine, Artesunate-Mefloquine, Artesunate-Sulfadoxine-Pyrimethamine and 
more recently Dihydroartemisinin-Piperaquine (Figure 2.6). However, resistance to 
artemisinin and its partner drugs have been reported in Southeast Asia (Noedl et al., 
2008, Dondorp et al., 2009, Ariey et al., 2014, Straimer et al., 2015, Phyo et al., 
2012).  
As drug resistance develops to existing medicines, new ones need to be introduced.  
Several new compounds from different drug classes are at various stages of R&D. 
Experts have also agreed on the need for new chemical agents that can prevent 
relapse of P. vivax infection and protect vulnerable populations, especially in early 
pregnancy (Wells et al., 2015). 
 
Figure 2.6: ACT used for the treatment of laboratory-confirmed uncomplicated 
Plasmodium falciparum malaria (February 2011).  
AL: Artemether–lumefantrine; AQ: Amodiaquine; AS: Artesunate; DHA: 
Dihydroartemisinin-piperaquine; MQ: Mefloquine; PPQ: Piperaquine; PQ: 
Primaquine; SP: Sulfadoxine/pyrimethamine. 
Source: (Mutabingwa and Adam, 2013) 
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Single Encounter Radical Cure and Prophylaxis (SERCaP) is being proposed as a 
silver bullet for the eradication of malaria.  SERCaP should be capable of radical 
cure, be suitable for mass administration and be able to have a prophylactic effect. 
Radical cure implies the elimination of all parasites (including the long-lived 
hypnozoites of P. vivax or P. ovale in the liver). The drug should be suitable for mass 
administration and have an excellent safety profile as it will be administered to 
healthy subjects. Any candidate for use as SERCaP should provide prophylaxis for 
at least one month following treatment, to outlast the development period of 
Plasmodia parasites in anopheline mosquitoes. The ideal scenario for malaria 
eradication would be a drug that is suitable for mass administration because it 
provides a prophylactic effect and acts against P. vivax as well as P. falciparum. It is 
clear that a drug with this profile may take a long time to develop, but the 
development of new medicines that meet some of these essential requirements 
could dramatically improve chances of elimination and eradication (malERA 
Consultative Group on Drugs, 2011). 
2.9.3 CHEMOPREVENTION OF MALARIA 
Chemoprevention was originally used with the aim of interrupting transmission. 
Although this failed, the administration of antimalarial drugs has repeatedly resulted 
in marked reductions in the prevalence of malaria and the incidence of clinical 
attacks (Greenwood, 2004). The WHO currently recommends three 
chemoprevention strategies involving intermittent preventive treatment (IPT) among 
pregnant women (IPTp), infants (IPTi) and more recently, seasonal malaria 
chemoprevention (SMC).These involve the administration of full treatment course of 
an antimalarial medicine given to prevent the consequences of malaria infections by 
maintaining therapeutic drug levels in the blood throughout the period of greatest 
malarial risk. The treatment course is given irrespective of whether the individual is 
infected with malaria. The aim is to prevent malarial illness. 
IPTp is to be given to pregnant women at routine antenatal visits in areas with 
moderate to high malaria transmission in sub-Saharan Africa. IPTi should be 
delivered to infants through immunisation services in regions with moderate to high 
malaria transmission in sub-Saharan Africa while SMC is recommended to be 
administered to children less than five years of age during the  rainy season which is 
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associated with higher malaria transmission in the Sahel sub-region of Africa (World 
Health Organization 2012e) 
These interventions target specific population groups in specific transmission 
settings in Africa and research has demonstrated that they are effective, cost-
effective and safe for preventing malaria in the target populations (World Health 
Organization, 2012a, World Health Organization, 2010a). IPTp has been discussed 
in greater detail in Section 2.11.1. 
2.9.4 VACCINATION 
Lots of time, effort and money have been spent on the development of malaria 
vaccines. Developing a vaccine against this pathogen has been a tremendous 
challenge because even after multiple infections, adults in malaria-endemic regions 
naturally acquire only partial immunity against the disease (Doolan et al., 2009). 
Despite considerable efforts over the past 40 years, there is currently no approved 
malaria vaccine. 
Malaria is a protozoan disease, with an active antigenic variation that distinguishes it 
from the viruses and bacterial toxins that have been successful vaccine targets 
(Rappuoli and Aderem, 2011).   
The most advanced malaria vaccine, Mosquirix (the peptide RTS, S and the 
proprietary AS01 adjuvant, which contains monophosphoryl lipid A and QS 21), was 
co-developed by GlaxoSmithKline, the PATH Malaria Vaccine Initiative, the Walter 
Reed Army Institute of Research, USA, and the Bill and Melinda Gates Foundation. 
It targets the circumsporozoite protein of P. falciparum and is boosted with the potent 
ASO adjuvant (Wells et al., 2015).  Mosquirix provides efficacy against all episodes 
of malaria with 55% protection in children but only 33% protection in infants (RTS, 
2014). The WHO has recently recommended pilot implementation be done to 
understand how to use the vaccine best. 
2.10 MALARIA IN PREGNANCY 
MiP is a significant public health problem with deleterious adverse effects to the 
mother and foetus. An estimated 125 million living in malaria-endemic areas become 
pregnant each year (Dellicour et al., 2010), and pregnancy increases the risk of 
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malaria infection and the severity of the disease compared to non-pregnant women 
of the same age (Desai et al., 2007). This increased vulnerability can be attributed to 
the immunological changes and hormonal factors induced by pregnancy (Rogerson 
et al., 2007b). Also, the higher attractiveness of pregnant women to mosquitoes and 
the behavioural and physiological changes associated with pregnancy are believed 
to contribute (Lindsay et al., 2000, Ansell et al., 2002). P. falciparum infection in 
pregnancy is associated with increased risks of maternal and foetal complications 
including maternal anaemia, stillbirth, premature delivery, low birth weight (LBW), 
perinatal and neonatal morbidity & mortality (Breman et al., 2004). 
2.10.1 RISK FACTORS 
Maternal factors associated with the risk of MiP include age, parity, and gestational 
age. Younger maternal age is known to increase the risk of malaria infection (Hamer 
et al., 2009, Ayoola et al., 2012), independent of parity (Hamer et al., 2009). The 
effect of MiP is parity-specific with the risk decreasing with increased gravidity 
(Ayoola et al., 2012, Hamer et al., 2009, Kalilani et al., 2010, Valea et al., 2012). The 
peak of malaria prevalence seems to occur during the second trimester (Agbor-Enoh 
et al., 2003) although a study has reported higher malaria prevalence in the first 
trimester compared to the second and third trimesters (Coulibaly et al., 2007). 
2.10.2 ADVERSE EFFECTS OF MALARIA INFECTION 
The effect of malaria infection during pregnancy depends on the amount of acquired 
immunity, which is dependent on the intensity of transmission. Pregnant women 
resident in areas of low and unstable P. falciparum malaria transmission, have little 
or no immunity and the adverse effects of MiP include stillbirth, miscarriage or 
maternal death. However, among pregnant women resident in stable transmission 
areas with considerable acquired immunity, the predominant adverse effects are 
maternal anaemia, placental malaria and low birth weight (World Health 
Organization, 2008) and asymptomatic infections are common. Also in these areas, 
the risk of low birth weight is higher when women have placental malaria especially 
during first pregnancies (Desai et al., 2007, White et al., 2014). Maternal mortality 
associated with malaria is probably under-reported. However, it has been reported 
as an important cause of death in several studies (Romagosa et al., 2007, Anya, 
2004, Ali et al., 2012, Somigliana et al., 2011). 
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In high transmission settings, malaria increases the risk of low birth weight. The 
mechanism is mainly through intrauterine growth retardation (IUGR) rather than pre-
term delivery, as most infections in these settings are asymptomatic (Takem and 
D'Alessandro, 2013). A meta-analysis of cross-sectional data from 32 African 
countries, showed malaria prevention during pregnancy was associated with 21% 
(95% CI; 14 to 27) relative risk reduction in LBW (Eisele et al., 2012).  
Congenital malaria may occur in the neonatal period and can thus contribute to 
infant morbidity and mortality (Bardaji et al., 2011). Placental malaria, especially 
active infection, has also been linked to neonatal and infant mortality (Bardaji et al., 
2011). Malaria infection during pregnancy increases the risk of infant and perinatal 
mortality, by causing LBW. Although the long-term effects of MiP have not been 
studied, malaria causes IUGR which results in LBW. LBW may be related to 
diseases occurring during adulthood, including some cancers and the metabolic 
syndrome (Christensen et al., 2011). 
2.10.3 PATHOPHYSIOLOGY 
A unique characteristic of P. falciparum is that infected erythrocytes in pregnant 
women adhere to chondroitin sulphate A (CSA) molecules, and sequester along the 
endothelial and syncytiotrophoblast cells of the placenta (Fairhurst and Wellems, 
2006, Cserti and Dzik, 2007, Rogerson et al., 2007a). For this reason, screening of 
peripheral blood may fail to detect infection of the placenta (Gosling et al., 2010). 
Chronic infection is often associated with IUGR whilst acute infection is more often 
the cause of miscarriage or stillbirth (Brabin et al., 2004). During pregnancy, the 
parasite antigens expressed on infected erythrocytes are known as variant surface 
antigen-pregnancy associated malaria (VSAPAM). They are different from the 
antigens normally expressed in non-pregnant individuals. In stable transmission 
settings, these VSAPAM are not recognised by the immune system, and this is 
responsible for primigravidae being at higher risk (Staalsoe et al., 2004). The binding 
of the variant surface antigen (VAR2CSA) with chondroitin sulphate A is connected 
to the pathology of falciparum malaria in pregnancy (Salanti et al., 2004, Ndam et al., 
2005). The VAR2CSA belongs to the family of the erythrocyte membrane protein 
(PfEMP1). It is encoded by the var2csa gene, and it is expressed in pregnant women 
with falciparum malaria (Sander et al., 2011). Levels of anti-VAR2CSA specific 
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immunoglobulin G (IgG) increase with parity, are only found in women and are 
associated with a favourable pregnancy outcome (Sander et al., 2011, Ndam et al., 
2005). 
Increased cortisol levels have also been associated with increased risk of MiP 
(Bouyou-Akotet et al., 2005). Rosetting, commonly observed in non-pregnant women 
is very rare in pregnant women with falciparum malaria (Rogerson et al., 2000). LBW 
as a result of IUGR is associated with maternal anaemia (Tako et al., 2005) and 
elevated levels of cytokines (Thévenon et al., 2010). This appears to be due to 
chronic infections that cause reduced foetal circulation and placental insufficiency 
(Takem and D'Alessandro, 2013). 
2.10.4 CLINICAL PRESENTATION 
The clinical presentation of malaria disease ranges from severe and complicated, to 
mild and uncomplicated, to asymptomatic malaria. In low transmission settings, 
severe MiP is usually associated with hypoglycaemia, pulmonary oedema, and 
severe anaemia. Mortality in pregnant women with severe malaria has been reported 
to be between 9% and 12% (Dondorp et al., 2005). In stable transmission settings, 
the clinical signs of MiP are usually non-specific and suspected malaria cases should 
be confirmed by parasitological diagnosis (World Health Organization, 2015c).  
Routine laboratory diagnosis of malaria is mostly based on microscopic detection of 
Plasmodium parasites in Giemsa-stained blood slides. Microscopy enables 
speciation, detection of gametocytes, and parasite density estimation. However, this 
technique is relatively laborious and the detection limit ~20 parasites/µL (Beurskens 
et al., 2009, Takem and D'Alessandro, 2013). Therefore, a considerable proportion 
of infected pregnant women would not be detected because of extremely low 
parasite densities or parasites sequestered in the placenta. 
 RDTs to detect Plasmodium-specific antigens (proteins) in whole blood of infected 
people have emerged as an attractive alternative to microscopy. However, the 
sensitivity of RDTs is lower than that of microscopy for diagnosing MiP. However, 
diagnosis can be made quicker than with microscopy and the time and amount of 
training required for their use are minimal.  However,  even though RDTs can detect 
malaria antigens, they cannot estimate the parasite density. The currently available 
RDTs come in various formats (dipstick, cassette or hybrids) and contain antibodies 
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bound to specific antigens, such as histidine-rich protein II (HRP2) unique to P. 
falciparum, pan-specific and species-specific plasmodium lactate dehydrogenase 
(pLDH) or aldolase specific to all the major Plasmodium species (P. falciparum, P. 
vivax, P. malariae, P. ovale) (World Health Organization, 2015d). A limitation is that 
PfHRP2-based tests might remain positive for weeks after acute infection, which 
limits their usefulness in stable transmission settings (White et al., 2014).  
The sensitivity of RDT on peripheral blood infections confirmed by microscopy/or 
PRC as a reference test among pregnant women ranged from 49% to 91% across 
West Africa. The study also found RDT sensitivity to be lower at the time of delivery 
relative to earlier time points in pregnancy (Williams et al., 2016). 
PCR, which detects parasite DNA, can also be used for the diagnosis of malaria 
infection. However, it is not readily available in health facilities because it is 
expensive to setup. In stable transmission settings, the sensitivity of PCR was >80% 
when using microscopy as the reference (Kattenberg et al., 2011). 
2.11  PREVENTION OF MALARIA IN PREGNANCY 
The use of ITNs, including LLINs in addition to intermittent preventive treatment in 
pregnancy (IPTp) with SP, are the most widely used interventions to prevent MiP. 
2.11.1 INTERMITTENT PREVENTIVE TREATMENT 
Following the spread of resistance to CQ (Sirima et al., 2003) and poor compliance 
(Kaseje et al., 1987, Helitzer-Allen et al., 1993) with weekly CQ chemoprophylaxis in 
pregnant women, IPTp with SP was investigated as an alternative. SP was cheap to 
implement, had an excellent safety profile, and was easier to administer being a 
single dose treatment. Thus, it was quickly recommended by the WHO as policy for 
areas of high malaria transmission. Initially, a full course of SP was to be given twice 
during pregnancy, beginning in the second trimester after quickening and provided 
partial protection (World Health Organization, 2004). Currently, a minimum of three 
doses of SP is recommended to provide continuous preventive effects. The success 
of IPTp led to the adaptation of this approach in infants and children. 
 Currently, 36 sub-Saharan African countries have adopted an IPTp policy even 
though coverage among pregnant women who actually received at least two doses 
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of SP remains low, particularly in Nigeria and the Democratic Republic of Congo 
(DRC) (World Health Organization, 2015a).  SP resistance spread emerged in 
Southeast Asia much faster than was the case with CQ and is increasing in many 
parts of Africa (White, 1992). This has led to the evaluation of alternative drugs. 
Studies of amodiaquine and mefloquine have not found definite evidence of superior 
benefit to SP. Also, these drugs were found to have more adverse side effects than 
SP (Clerk et al., 2008, Gonzalez et al., 2014). 
More recently, dihydroartemisinin-piperaquine has been evaluated for use in IPTp 
and showed promising results (Desai et al., 2015, Kakuru et al., 2016). A potential 
alternative strategy for preventing malaria in pregnancy being evaluated is 
intermittent screening and treatment. 
The percentage of pregnant women receiving at least three doses of intermittent 
preventive treatment in pregnancy (IPTp) has increased since revisions to the WHO 
recommendation in 2012 (World Health Organization, 2015a). According to the 2015 
World Malaria Report, in 2014 an estimated 52% of eligible pregnant women 
received at least one dose of IPTp, 40% received two or more doses, and 17% 
received three or more doses of SP.  
However, there are huge gaps between the proportion of women attending antenatal 
care (ANC) clinics and the proportion receiving one or more doses of IPTp. These 
represent missed opportunities to deliver IPTp at these clinics. In sub-Saharan 
Africa, the proportion of women receiving IPTp varies across the continent, with 10 
countries reporting more than 60% of pregnant women receiving at least one dose, 
and another nine countries reporting more than 80% receiving one or more doses 
(World Health Organization, 2015a). 
Some important barriers to the provision of IPTp have been identified as unclear 
policy and guidance on IPTp; general health care system issues, such as stockouts 
and user fees; poor organisation in health facilities, leading to poor quality of care; 
poor healthcare provider performance, including misunderstanding over the timing of 
each IPTp dose. In some settings, women’s poor antenatal attendance affects IPTp 
uptake. Key determinants of IPTp coverage have been identified to be education, 
knowledge about malaria/IPTp, parity, socioeconomic status, and the number and 
timing of antenatal clinic visits (Hill et al., 2013). 
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2.11.2 INTERMITTENT SCREENING AND TREATMENT 
Recent success in malaria control efforts has prompted renewed discussions about 
malaria elimination. This has led to a shift in attention from targeting clinical malaria 
to also identifying and treating asymptomatic malaria parasitaemia. The rationale 
being that, as endemic countries achieve sustained results in malaria control, the 
persistence of malaria would rely mainly on asymptomatic carriers (AC) who harbour 
the P. falciparum asexual forms, with or without gametocytes but do not present 
clinical symptoms of the disease (Kern et al., 2011).  
The transmission of P. falciparum parasites from the host (humans) to the vector 
(mosquitoes) requires the presence of infectious gametocytes in the host’s 
peripheral circulation. Thus, ACs who would not usually seek treatment, then 
become a reservoir of parasites for the inoculation of newly-hatched mosquitoes and 
this contributes to the transmission of the disease (Kern et al., 2011). Also, these 
individuals with asymptomatic parasitaemia are at risk of developing anaemia and 
may progress to clinical malaria (Tiono et al., 2013). 
The detection and treatment of ACs of P. falciparum as a novel strategy for malaria 
control has been previously considered (Ogutu et al., 2010, El-Sayed et al., 2007, 
Dunyo et al., 2006a). The WHO has noted that infectivity-reducing drug regimens will 
play a useful role in maintaining the reductions in disease transmission achieved 
through integrated malaria control programmes (World Health Organization, 2015c). 
Among pregnant women in malaria endemic countries, a significant proportion of 
malaria infections are asymptomatic. Therefore eliminating this reservoir of infection 
will be crucial in attaining malaria elimination and then eradication. 
The potential of IST as an intervention for malaria prevention was first highlighted by 
modelling studies (Griffin et al., 2010, Kern et al., 2011). Griffin and colleagues 
demonstrated the potential of mass screening and treatment (MSAT) combined with 
scale up in coverage of LLINs and use of ACTs to reduce transmission levels  from 
60% to about 10% in the whole population (Griffin et al., 2010). 
The comparative efficacy of IST compared to IPT in pregnant women has been 
investigated in West Africa. The first trial in Ghana (Tagbor et al., 2010) randomised 
3,333 women into three intervention groups; standard IPTp-SP, ISTp with SP or 
ISTp with amodiaquine-artesunate (AQ+AS). This trial found ISTp with AQ+AS or SP 
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to be non-inferior to IPTp-SP in reducing the risk of low birth weight and third-
trimester severe anaemia. 
The subsequent multicentre trial was conducted in four West African countries 
(Ghana, The Gambia, Burkina Faso, Mali) enrolling 5,354 primi- or secundigravidae 
women. ISTp-AL was shown to be non-inferior to IPTp-SP in preventing low birth 
weight, anaemia and placental malaria (Tagbor et al., 2015). 
There has been general acceptability of this new intervention by pregnant women 
(Pell et al., 2014, Smith et al., 2010b) and health providers (Smith Paintain et al., 
2011). However, qualitative studies have identified some concerns amongst 
pregnant women. Some of these include fears about covert HIV testing and pain 
from finger pricks. Also, questions remain about adherence to a multiple dose 
antimalarial regimen during pregnancy. Community engagement is also required to 
educate communities on the consequences of asymptomatic malaria (Shuford et al., 
2016). 
2.12 TREATMENT OF MALARIA IN PREGNANCY 
For the management of malaria in pregnancy, it is recommended that pregnant 
women are treated only after parasitological confirmation of the diagnosis, to reduce 
unnecessary exposure to antimalarials of both the mother and the foetus.  
Women in the first trimester of pregnancy are usually excluded from clinical trials on 
the safety and efficacy of antimalarials in pregnancy so that the evidence is mostly 
from observational studies (Moore et al., 2016, Manyando et al., 2010, McGready et 
al., 2012, Mcgready et al., 2002). WHO recommends ACTs only in the second and 
third trimester. They may only be used if there are no suitable alternatives and are 
aimed at saving life. For uncomplicated malaria in the first trimester, the 
recommendation is 7 days’ oral quinine alone or combined with clindamycin (World 
Health Organization, 2015c) 
Nevertheless, in low-income countries, many pregnant women are exposed to ACTs 
in the first trimester from prescriptions early in pregnancy when women are not 
aware they are pregnant and from self-medication which is widespread (Mutabingwa 
and Adam, 2013).  Evidence suggests artemisinin derivatives are relatively safe in 
the first trimester of pregnancy. Recent studies have found artemisinin exposure 
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during the first trimester was not associated with increased risk of miscarriage 
(Dellicour et al., 2015), perinatal mortality, malformations, or developmental 
impairment (Manyando et al., 2010).    
In the second trimester, effective ACTs in the area, or 7 days artesunate plus 
clindamycin, or 7 days quinine plus clindamycin are recommended for uncomplicated 
malaria. (World Health Organization, 2015c).  In the case of severe malaria, 
parenteral artesunate and quinine are considered options.  
There is more experience on the use of artemisinin derivatives in the second and 
third trimesters of pregnancy, and several artemisinin compounds have been 
evaluated for the treatment of malaria in pregnancy. 
Clinical trials conducted in Tanzania and Ghana have shown amodiaquine (AQ) is 
efficacious in pregnant women with falciparum malaria (Tagbor et al., 2006, 
Mutabingwa et al., 2009). It was relatively safe and well tolerated but associated with 
some minor side effects like nausea, weakness, and dizziness. However, AQ is not 
recommended by WHO as monotherapy for malaria even in pregnancy. Also, cross 
resistance between CQ and AQ due to the accumulation of mutations in the Pfcrt 
gene has been established (Sa and Twu, 2010). 
There are fewer studies on the efficacy and safety of mefloquine (MQ) for the 
treatment of MiP. However, high cure rates have been reported in Thailand, for the 
combination of MQ and AS- cure rate of 98.2% at day 63 (McGready et al., 2000). 
One study (Briand et al., 2009) reported minor side effects with mefloquine. 
However, concerns about still births and neuropsychiatric disorders remain (Takem 
and D'Alessandro, 2013).  
DHAPQ is used in the Western Pacific for treating malaria in pregnant women 
(Poespoprodjo et al., 2011). A multicentre, randomised, open-label trial of four 
treatments (AL, AQ-AS, MQ-AS, DHAP) for malaria in pregnant women in four 
African countries found cure rates between 94% and 98%. However, drug-related 
adverse events such as poor appetite, asthenia, dizziness, nausea, and vomiting 
occurred significantly more frequently in the mefloquine–artesunate group (50.6%) 
and the amodiaquine– artesunate group (48.5%) than in the dihydroartemisinin–
piperaquine group (20.6%) and the artemether–lumefantrine group (11.5%) 
(PREGACT Study Group, 2016).  
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There is certainly more evidence available on the use of ACTs for malaria in 
pregnancy. However, the currently available evidence may not be sufficient for an 
immediate revision of the treatment guidelines as it relates to malaria in pregnancy. 
2.13 INVESTIGATIONAL PRODUCTS 
2.13.1 ARTEMISININ AND ITS DERIVATIVES 
Artemisinin and its derivatives are currently the mainstays of the treatment of 
malaria. 
Artemisinin is the active component developed from the leaves of the old Chinese 
herbal medicine Artemisia annua-sweet wormwood or qinghao which has been used 
for several centuries for the treatment of fever. The commonly used derivatives of 
artemisinin are artesunate, artemether, and dihydroartemisinin (Figure 2.7). Every 
form of artemisinin is converted to the active metabolite dihydroartemisinin (DHA).  
Artemisinins are very effective at rapidly clearing parasites by killing young, 
circulating ring-stage parasites and preventing further maturation and sequestration 
of these parasites (White, 2008). However, this is short-lived when used as a 
monotherapy due to its very short half-life and results in high rates of recrudescence. 
Thus, for effective treatment of malaria, artemisinin is combined with a long-acting 
blood schizonticide which will clear remaining parasites, thereby reducing the risk of 
developing resistance. Some drugs commonly used in combination with artemisinins 
are lumefantrine, mefloquine, piperaquine, SP, and amodiaquine. 
Unfortunately, fake or substandard antimalarials are widespread in many Asian and 
African countries, which compromises effectiveness, selects for antimalarial drug 
resistance, and reduces confidence in the health sector (White et al., 2014). 
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Figure 2.7: Chemical structures of artemisinins and semi-synthesized derivatives. 
2.13.2 ARTEMETHER-LUMEFANTRINE  
Artemether-lumefantrine was introduced in Nigeria in 2004 as the first line 
antimalarial drug for the treatment of uncomplicated malaria (World Health 
Organization, 2014b). The drug artemether-lumefantrine is a fixed combination of 
artemether-lumefantrine in the ratio 1(20mg, artemether): 6 (120mg, lumefantrine). It 
is indicated for the treatment of acute, uncomplicated infections due to Plasmodium 
falciparum or mixed infection including P. falciparum and strains from multi-drug 
resistant areas for all age groups. Artemether is a sesquiterpene lactone derived 
from the naturally occurring compound artemisinin (Tringali, 2011). It is the methyl 
ether of dihydroartemisinin while lumefantrine belongs to the aryl-amino-alcohol 
family and is a racemic mixture of a synthetic fluorene derivative. Both components 
act in the food vacuole of the malaria parasite. Lumefantrine interferes with the 
polymerization process that converts toxic haem, to non-toxic haemozoin while 
artemether may generate toxic, reactive metabolites as a result of the interaction 
between its endoperoxide bridge and haem iron (Aweeka and German, 2008, 
Chijioke-Nwauche, 2014). Artemether and lumefantrine have a secondary action 
involving the inhibition of nucleic acid and protein synthesis ( Novartis, 2012). 
Lumefantrine has a similar mechanism of action to halofantrine perhaps due to 
similarities in structure and pharmacokinetic properties. However, lumefantrine is 
very safe as it does not prolong the electrocardiographic QT interval (Van Vugt et al., 
1999). 
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2.13.3 SULFADOXINE-PYRIMETHAMINE 
Sulfadoxine-pyrimethamine (SP) was introduced following the development of 
widespread resistance to CQ. SP is a combination of sulfadoxine and 
pyrimethamine. Sulfadoxine is a broad-spectrum sulphanilamide antimicrobial which 
acts by inhibiting the synthesis of folic acid by bacteria and protozoa. Sulfadoxine 
competes with para-aminobenzic acid (PABA) for the bacterial 
enzyme dihydropteroate synthase (DHPS), thereby preventing the addition 
of PABA into dihydrofolic acid, the immediate precursor of folic acid. This leads to an 
inhibition of parasitic folic acid synthesis and de novo synthesis of pyrimidines and 
purines and subsequently cell growth arrest and cell death. 
Pyrimethamine is a synthetic derivative of ethyl-pyrimidine with potent antimalarial 
properties. Pyrimethamine is a blood schizontocide, which competitively inhibits 
dihydrofolate reductase (DHFR). DHFR is a key enzyme in the redox cycle for 
production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA 
and proteins. Figure 2.8 shows the chemical structures of sulfadoxine and 
pyrimethamine. 
   
Figure 2.8: Chemical structures of Sulfadoxine and Pyrimethamine. 
The synergistic effect of sulfadoxine with pyrimethamine has been effective as a 
combined antimalarial monotherapy against asexual erythrocytic forms of malaria 
parasites (trophozoites and schizonts). However, SP is ineffective against mature 
gametocytes within the sexual developmental phase.  
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SP is readily absorbed from the gastrointestinal tract after oral administration. 
Sulfadoxine and pyrimethamine have relatively long half-lives of 4.1 – 10.9 days and 
2.5 – 18.8 days respectively (World Health Organization, 2015c).  SP has a good 
safety profile in pregnancy. Compliance is high with SP as it can be delivered as a 
single dose treatment under observation by health workers. These attributes have 
led to high levels of IPT acceptance by pregnant women.  
Both sulfadoxine and pyrimethamine are generally considered safe in the second 
and third trimesters of pregnancy. However, nausea, vomiting, urticarial, rashes, 
headache and insomnia are documented side effects of SP. A rare adverse effect 
that could occur in persons with sensitivity to sulfa drugs is Stevens Johnson 
Syndrome. 
High doses (5mg daily) of folic acid adversely affects the antimalarial effects of SP. 
For this reason, a low dose (0.4mg daily) of folic acid is recommended in the ANC 
period. 
 
 
 
2.14 ANTIMALARIAL RESISTANCE 
Antimalarial drug resistance is defined as the ability of a parasite strain to survive or 
multiply despite the proper administration and absorption of an antimalarial drug at 
the normally recommended dose (World Health Organization, 2015c). It is a shift to 
the right of the dose-response curve and implies higher drug concentrations are 
required to achieve the same parasite clearance.  In many cases even the higher 
concentration results in treatment failure (White, 2004). Parasite resistance to 
antimalarial drugs has been recognised in three of the five malaria species that are 
known to affect humans: P. falciparum, P. vivax, and P. malariae. Antimalarial 
resistance to CQ and SP has been well established. Unfortunately, P. falciparum 
resistance to artemisinin has been detected in five countries of the Greater Mekong 
sub-region: Cambodia, Myanmar, the Lao People’s Democratic Republic, Thailand 
and Viet Nam. In many areas along the Cambodia–Thailand border, P. falciparum 
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has become resistant to most available antimalarial medicines (World Health 
Organization, 2014c). 
Cross-resistance further compounds the problem of antimalarial drug resistance. 
Cross-resistance implies that resistance to one drug results in resistance to other 
drugs in the same chemical family or with similar modes of action. During the past 
decades, several antimalarials had to be removed from markets after the spread of 
parasite resistance (World Health Organization, 2014c). 
It is important to distinguish between a failure to clear malaria parasitaemia or 
resolve clinical disease following treatment with an antimalarial drug and true 
antimalarial drug resistance. While drug resistance can cause treatment failure, not 
all treatment failure is due to drug resistance. The success of any antimalarial drug 
depends on the varying response of the parasites. Also, the various stages of the 
parasite life cycle differ in their susceptibility to different medicines.  
Medicines for the treatment of uncomplicated malaria ought to effectively eradicate 
parasites or reduce the parasite burden to the point that the humoral response can 
cope with the infection (White, 2002, White, 1998). Thus, an effective antimalarial 
drug treatment should cure malaria and reduce morbidity associated with treatment 
failures (World Health Organization, 2015c). Antimalarial drug resistance is often 
associated more with treatment failure than with prophylactic failure (Miller et al., 
2005). 
Antimalarial treatments are designed to sustain blood concentrations which are 
sufficient to restrict parasite multiplication until the last viable parasite has been 
eliminated from the body (White, 1997). To confirm the development of antimalarial 
drug resistance, the treatment regime must be proven to be inefficient despite being 
in the body in sufficient amounts and time periods to target a minimum of four 
asexual parasite life cycles (approximately six days for P. falciparum) (White, 1998).  
Sub-optimal drug concentrations increase the probability for drug-resistant parasites 
to emerge. These sub-optimal drug concentrations happen mainly as a result of 
improper dosing, poor pharmacokinetic properties, and fake drugs. Within the 
context of chemoprevention and chemotherapy, malaria infections acquired during 
the drug elimination phase of a prior antimalarial treatment can also expose 
parasites to sub-optimal drug concentrations (Petersen et al., 2011). The factors 
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influencing antimalarial drug resistance have also be summarised in three categories 
which include the nature of the parasite, human immune responses and 
pharmacological properties of the drug (Travassos and Laufer, 2009). 
Repeated exposure to P. falciparum leads to the development of slowly acquired 
immunity in communities (White, 2004). Individuals with this acquired immunity tend 
to have better treatment outcomes when given antimalarial drugs compared to those 
without any background immunity (Mayxay et al., 2001).  
Individuals with lower immunity such as children and pregnant women or persons 
with opportunistic infections such as HIV are more vulnerable to antimalarial drug 
resistance. 
2.15 EMERGENCE AND SPREAD OF DRUG RESISTANCE 
The evolution of antimalarial drug resistance has been characterised by three 
events: the appearance of mutations, the establishment of mutations and the spread 
of mutations (Smith et al., 2010a). Firstly, the emergence of resistance is 
characterised by infections with de novo mutations whereby the sensitive parasites 
are initially the majority strain until treatment is administered and the proportion of 
resistant strains eventually outnumber the sensitive forms (Smith et al., 2010a). 
However, the genetic events that lead to drug resistance are spontaneous and rare 
(either mutations or change in the copy number of genes encoding for a parasite 
target) and are thought to be independent of the drug used (White, 2004). The 
second phase is when resistance becomes established after its initial appearance 
and as mutant parasites persist and spread within the population (Smith et al., 
2010a). This establishment phase depends on the fitness cost of mutant parasite 
strains which in turn depends on its biological cost versus the benefits conferred by 
drug pressure (Smith et al., 2010a). Parasites carrying mutations depend on 
sustained drug pressure and once this drug pressure is reduced, the mutant strains 
will eventually be outnumbered by sensitive strains. The third phase, `spread’ 
involves displacement of sensitive parasite strains with resistance strains within the 
population and this is affected by the malaria transmission intensity in communities.  
The emergence of resistance in Plasmodium depends on several factors, including 
the mutation rate of the parasite, the fitness costs associated with the resistance 
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mutations, the overall parasite load, the strength of drug selection, and the treatment 
compliance (Petersen et al., 2011).  
P. falciparum parasites from Southeast Asia seem to have an ‘accelerated 
resistance to multiple drugs’ phenotype which gives them an increased propensity to 
develop drug resistance (Rathod et al., 1997)  Also, the emergence of drug-resistant 
parasites can also be accelerated by strong drug selection pressure, which 
decreases the prevalence of competing sensitive wild type parasites (Petersen et al., 
2011). 
In high-transmission regions, infections acquired after treatment from a previous 
malaria episode are common and result in the exposure of parasites to sub-
therapeutic drug concentrations. This selects for drug-tolerant parasites, which may 
be a precursor to full resistance (Stepniewska and White, 2008). The period during 
which sub-therapeutic concentrations are present within the patient is prolonged in 
antimalarials that possess a long half-life (Hastings and Watkins, 2006) and increase 
the probability of resistance developing.  The intensity of transmission also plays an 
important part in determining if parasites are effectively transmitted during a 
mosquito blood meal.  
If mutations conferring drug resistance are associated with a significant fitness cost, 
they are more likely to be outcompeted by sensitive parasites and not transmitted 
efficiently. The spread of resistant parasites is also affected by the impact of 
antimalarials on the gametocytes, which are the transmissible stages of the parasite. 
Artemisinins have been shown to decrease the number of gametocytes carried by a 
patient, thereby reducing transmission (Okell et al., 2008). However, both SP and 
CQ elevate the gametocytaemia (White, 2008). In addition, drug resistance may 
enhance transmission if drug selection pressure diminishes the viability of sensitive 
gametocytes in a polyclonal infection, increasing the propensity for transmitting drug-
resistant parasites (Hastings, 2006). 
2.16 SP DRUG RESISTANCE MECHANISM 
The antifolate class of drugs consists of compounds that bind enzymes essential for 
folate biosynthesis in the parasite. The most widely used anti-malarial drug within 
this class is SP. SP is a blood schizonticide that inhibits folate metabolism which is 
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an essential biochemical pathway for P. falciparum survival. While vertebrates use 
preformed folate from their diet, microorganisms and plants synthesise folates de 
novo from guanosine triphosphate, p-amino benzoic acid (PABA) and glutamate, 
using a chain of enzymes (Warhurst, 2002). Sulphadoxine mimics para-
aminobenzoic acid (PABA) in competing for the active site on the dihydropteroate 
synthase (DHPS) enzyme. The PABA interaction with DHPS would normally lead to 
folic acid production in the parasite, but it is interrupted in the presence of 
sulphadoxine (Olliaro, 2001). Pyrimethamine inhibits plasmodial dihydrofolate 
reductase (DHFR) and thereby prevents the nicotinamide adenine dinucleotide 
phosphate (NADPH) dependent reduction of dihydrofolate to tetrahydrofolate 
(Olliaro, 2001). 
Mutations in the dhfr and dhps genes of P. falciparum parasites have been 
associated with decreased parasite sensitivity to the antifolate drugs. The 
appearance and accumulation of mutant SNPs in dhfr and dhps genes have been 
associated with tolerance to SP treatment (Kublin et al., 2002, Vinayak et al., 2010). 
Assessment of molecular markers of resistance present in a geographical area is 
one of the methods for assessing antimalarial drug resistance. Molecular markers of 
SP resistance are presented below. 
2.17 MOLECULAR MARKERS OF SP DRUG RESISTANCE 
Since the late 1980s and 1990s specific point mutations of the dhfr and dhps gene 
encoding DHFR and DHPS were implicated in SP resistance (Cowman et al., 1988, 
Peterson et al., 1988, Brooks et al., 1994, Triglia and Cowman, 1994). Mutations at 
seven dhfr codons (16, 50, 51, 59, 108, 140 and 164) and six dhps codons (431, 
436, 437, 540, 581 and 613) have since then been isolated as molecular markers for 
SP resistance. The mutation at codon I431V is novel and is the substitution of valine 
for isoleucine at codon 431. The significance of this I431V dhps mutation to antifolate 
resistance remains unclear. However it is has been detected in occurrence with 
437G, 581G and 613S from Nigerian isolates (Sutherland et al., 2009). Mutations at 
codons 581 and 613 have long been associated with SP resistance (Plowe et al., 
1997).  The new dhps I431V mutation was recently detected, at a prevalence of 
9.8% in Cameroon and was associated with other dhfr/dhps alleles to form an 
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octuple N51I, C59R, S108N/I431V, S436A, A437G, A581G, A613S mutant (Chauvin 
et al., 2015). 
There appears to be a relationship between identified molecular markers and clinical 
failure of antifolates. Pfdhfr and Pfdhps mutations have been associated with an 
enhanced transmission of gametocytes to mosquitoes despite low levels of in vivo 
treatment failure (Hallett et al., 2006, Méndez et al., 2002).   
Genotypes consisting of multiple mutations in the dhfr gene have evolved across the 
world and are most often associated with higher levels of resistance than the single 
mutant genotypes. The triple dhfr mutant genotype consisting of N51I, C59R, and 
S108N has demonstrated a strong association with in vivo SP treatment failure 
(Kublin et al., 2002, Happi et al., 2005). The addition of the N51I, C59R, and I164L 
mutations in the presence of S108N confers high levels of resistance to both 
cycloguanil and pyrimethamine and cycloguanil (Foote et al., 1990, Sirawaraporn et 
al., 1997). 
Data from several malaria endemic areas suggest an asymmetric selection of 
resistant genotypes beginning with mutations in dhfr and then by those in dhps 
(Sibley et al., 2001). The dhps mutations A437G, K540E, and A581G are particularly 
associated with established sulfadoxine-pyrimethamine failure in vivo (Dunyo et al., 
2006b, Alker et al., 2008, Happi et al., 2005). However, the quintuple mutant 
genotype consisting of the double Pfdhps mutant genotype (A437G, K540E) in 
combination with the Pfdhfr triple mutant genotype (S108N, N51I, C59R) is a better 
predictor of clinical failure than either multiple mutant genotype alone (Mugittu et al., 
2004). A Nigerian study (Happi et al., 2005) established the quintuple mutant 
genotype was strongly associated with SP treatment failure in children less than five 
years. 
 
 
 
 
Table 2.2 and Table 2.3 show the amino acid substitutions and the underlying 
sequence changes in the three letter code for each codon. 
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Table 2.2: Molecular markers of dhfr resistance. 
dhfr 
Codon 
 
Sensitive 
 
Resistant 
16 GCA Ser(S) 
TCA 
Val(V) 
GTA 
50 Cys(C) 
TGT 
Arg(R) 
CGT 
 
51 Asn(N) 
AAT 
Ile(I) 
ATT 
 
59 Cys(C) 
TGT 
Arg(R) 
CGT 
 
108 Ser(S) 
AGC 
Asn(N) 
AAC 
Thr(T) 
ACC 
140 Val(V) 
GTT 
Leu(L) 
CTT 
 
164 Ile(I) 
ATA 
Leu(L) 
TTA 
 
 
 
Table 2.3: Molecular markers for dhps resistance. 
dhps 
Codon 
 
Sensitive 
 
Resistant 
431 Val (V) Ile (I)  
436 Ser(S) 
TCT 
Ala(A) 
GCT 
Cys(C) 
TGT 
Phe(F) 
TTT 
437 Ala(A) 
GCT 
Gly(G) 
GGT 
  
540 Lys(K) 
AAA 
Gly(E) 
GAA 
  
581 Ala(A) 
GCG 
Gly(G) 
GGG 
  
613 Ala(A) 
GCC 
Ser(S) 
TCC 
Thr(T) 
ACC 
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In East Africa SP clinical failure has been established and is now widespread 
(Iriemenam et al., 2012, Karema et al., 2010, Eriksen et al., 2008) with a high 
frequency of the quintuple mutations in Pfdhfr (51I/59R/108N) and the double 
mutation in Pfdhps (S437G/K540E).There has also been the emergence of A581G 
mutation (Gesase et al., 2009, Iriemenam et al., 2012, Sendagire et al., 2005). 
Consequently, continued monitoring of Pfdhfr and Pfdhps mutations in West Africa is 
essential due to the use of sulfadoxine-pyrimethamine for Intermittent Preventive 
Treatment of malaria in pregnant women and infants in Africa. 
 
2.18 NIGERIA AND THE STUDY SITE 
2.18.1 GEOGRAPHY 
Nigeria is on the West coast of Africa and has a surface area of 923,708 square 
kilometres lying between Latitudes 4° and l 4°N and Longitudes 2° and 1 5°E. 
Nigeria is bounded by Cameroon on the East, Benin on the West, Chad to the North- 
East, the Niger Republic to the North and on the south by the Atlantic Ocean. The 
topography of its landmass is diverse with its terrain consisting of lowlands in the 
South, plateaus, and hills towards the Centre, mountains in the South East and 
plains in the North. The highest elevation is Chappal Waddi at 2,419m in Taraba 
State in the North-Eastern region of the country. The Rivers Niger and Benue run 
from the North-Western and North-Eastern parts of the country respectively with their 
confluence in Lokoja from which it runs to the Delta region in the South where it 
interconnects with the Atlantic Ocean. The capital city is Abuja. 
2.18.2 DEMOGRAPHY 
Nigeria is the most populous country in Africa. The latest estimates of the population 
of Nigeria is reported to be 181.6 million inhabitants in 2015 (United States Census 
Bureau, 2015). About 44% of the population is less than 15 years of age with only 
5% aged above 60 years and the median population age is 18 years. The proportion 
of the population pregnant during one year is put at 5%.The country has a total 
fertility rate of 6.6 however, one in eight children die before their fifth birthday. Life 
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expectancy at birth in Nigeria is 55 and 54 years in females and males respectively 
(World Health Organization, 2015e).  
The bulk of the people are farmers living in rural areas where there is a shortage of 
access to infrastructure and health facilities. There is an ever growing rural -urban 
drift resulting in pressure on existing facilities in the towns and cities. Maternal 
mortality ratio in 2014 was estimated to be 820/ I00,000 live births (World Health 
Organization, 2015f). Table 2.4 shows some other key socioeconomic and 
demographic data for Nigeria. 
Table 2.4: Key Socio-Economic and Demographic information 
Variable/Indicator Value Source 
Population (2016) 181.6 
million 
US Census Bureau, 2015 
Crude Birth Rate, 2013 41 
 
UNICEF, 2015 
Crude Death Rate per 1000, 2013 13 UNICEF, 2015 
Total Fertility Rate 2013 6.6 UNICEF, 2015 
Under-5 mortality rate (U5MR), 2013 117 UNICEF, 2015 
Infant mortality rate (under 1), 2013 74 UNICEF, 2015 
Neonatal mortality rate 2009 37 UNICEF, 2015 
Maternal Mortality Ratio 2009-2013 550 UNICEF, 2015 
Antenatal Attendance (%) At least Once  61 UNICEF, 2015 
GDP (US$) 2014 568.5 
billion 
World Bank, 2014 
GDP per capita (US$) 2014 1,091 World Bank, 2014 
Life expectancy at birth (years) 2015 53 UNICEF, 2015 
Total adult literacy rate (%) 2009-2013 51 UNICEF, 2015 
Primary school net enrolment ratio (%) 2009-2013 66 UNICEF, 2015 
 
2.18.3 ECONOMY 
Agriculture is the primary source of livelihood for most of the population who are 
subsistence farmers. The nation's principal source of income is crude oil exports. 
Other sources of revenue include mining and export of cash crops. Nigeria is 
currently classified as a lower middle-income country by the World Bank. In 2014, 
the Gross Domestic Product (GDP) was 568.5 billion USD; while GDP per capita 
was 1,091 USD, with a GDP growth rate of 6.3% (World Bank, 2014). Most health 
expenses are borne by families and individuals as "out of pocket" expenses while 
limited health insurance services are available, especially to civil servants and some 
rural communities. 
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2.18.4 CLIMATE 
The climate is arid in the North, with an annual rainfall of 600 - 1,000 mm lasting for 
3-4 months, and predominantly humid in the South with a yearly average of 1,300-1 
,800 mm but in some coastal areas may be up to 2,500 mm) lasting for 9-12 months 
(Federal Ministry of Health, 2015). Rainfall is highest in the Northern parts of the 
country between the months of June and September and from March to November in 
the Southern areas, which usually coincides with the peak incidence of malaria. The 
country's vegetation characterised by Sahel Savannah in the far North, Guinea 
Savannah in the Middle Belt, and rain forest in the South with mangrove forest in the 
coastal areas. As a result of increases in rainfall in Nigeria and neighbouring 
countries, flooding has now become a frequent occurrence in all parts of the country, 
most especially in riverine communities and the Niger Delta Region. 
2.18.5 EPIDEMIOLOGY OF MALARIA 
Malaria is holoendemic in Nigeria with transmission all year round. Nigeria has two 
main seasons in the year, the dry season (October to March) and the rainy season 
(April to September) with a peak of the rains between May and July when malaria 
transmission is very intense. The rainfall pattern in Nigeria varies with the South 
having more rains than the North. Annual rainfall increases southward from 500-750 
millimetres in the north to about 2,000 millimetres in the coastal zone with an 
average of more than 3,550 millimetres in the Niger Delta region.  
Malaria is transmitted all through Nigeria, with the entire population at risk (World 
Health Organization, 2014b).  According to the National Malaria Elimination 
Programme Strategic Plan 2014-2020, malaria accounts for about 60% and 30% of 
outpatient visits and hospitalizations in Nigeria respectively. It is a leading cause of 
mortality in children under five years of age, and is responsible for an estimated 
300,000 deaths yearly. It also contributes to an estimated 11% of maternal mortality, 
25% of infant mortality, and 20% of under-five mortality (Federal Ministry of Health, 
2015). Malaria is also a foremost cause of mortality in children under five and 
contributes to an estimated 25% of infant mortality and 11% of maternal deaths. 
Treatment of malaria illnesses accounted for 40% of the curative health care cost 
incurred by households. Intensity and seasonality of transmission vary by region. 
46 
 
The duration of the transmission season ranges from year-round transmission in the 
south to three months or less in the north. P. falciparum is the predominant malaria 
species.  
Thus, malaria remains one of the leading causes of morbidity and mortality in 
Nigeria. Nigeria and the Democratic Republic of Congo account for 38% of the global 
estimate of malaria deaths (World Health Organization, 2015a).  
The direct financial loss to the Nigerian economy due to malaria is estimated to be 
about 132 billion Naira (about 8.8million US dollars) in the form of treatment costs, 
prevention and loss of person-hours annually (National Population Commission, 
2012). 
2.18.6 MALARIA TRANSMISSION 
Recently, modelling studies based on age-corrected malaria point prevalence data in 
children 2- 10 years and the effects of temperature, rainfall, distance to major rivers 
and urbanization have been used to predict malaria risk across Nigeria (Snow et al., 
2013). It was found that as at 2010, 85% of Nigerians lived in areas supporting 
mesoendemic transmission, 15% used to live under conditions of hyper-
holoendemicity and areas within the north (Abuja, Adamawa, and Borno State) 
support hypoendemicity. 
2.18.7 MALARIA SPECIES AND VECTORS 
The dominant species of malaria parasites in Nigeria is P. falciparum (95%). There 
are also mixed infections with other Plasmodium species. The other non-falciparum 
species in Nigeria are P. malariae (9.8%) and P. ovale (5.8%) and mixed infections 
(10.4%) (World Health Organization, 2012e). 
In Nigeria, the major malaria vectors include the An. gambiae complex (An. gambiae 
s.s. and An. arabiensis) and the Anopheles funestus group. These three species are 
widely distributed across the country, from the mangrove and coastal areas of the 
south to the Sahel savannah of the far north. An. gambiae and An. arabiensis 
typically breeds in sunlit, shallow, temporary bodies of fresh water such as ground 
depressions, puddles, pools and hoof prints. An. funestus breeds in permanent or 
semi -permanent body of fresh water with emergent vegetation; such as swamps, 
large ponds which sustain malaria transmission during the dry season. An. melas, 
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another member of the An. gambiae complex breeds in the mangrove and coastal 
areas of the south-south and southwestern zones (Federal Ministry of Health, 2015). 
The molecular forms (M and S) of An. gambiae s.s. have been found in Nigeria 
(Awolola et al., 2005). An gambiae s.s. feeds primarily on humans (anthropophagic) 
and rest indoors (endophilic) while An. arabiensis feeds on humans and other 
animals and mainly rests outdoors (exophilic). An. gambiae s.s. also tend to have 
higher sporozoite rates compared to An. arabiensis. An. funestus feed on both 
humans and other animals predominate in the forest, rest indoors. Where the major 
malaria vectors co-exist, infection rates have been reported to be higher in An. 
gambiae s.s. followed by An. funestus and An. arabiensis (Federal Ministry of 
Health, 2015).  
With the scaling up of vector control interventions, a decline in vector densities and 
transmission is expected. However, as LLIN and IRS coverage increases, there 
remains the possibility of behavioural adaptation of malaria vectors. 
2.18.8 MALARIA CONTROL IN NIGERIA 
Nigeria is in the malaria control phase. Early diagnosis and prompt treatment of 
malaria with effective antimalarial drugs is the main strategy for malaria control.  
Malaria diagnosis and ACTs are provided at no cost for all age groups in public 
sector facilities since 2009. Since 2004, artemether-lumefantrine and artesunate-
amodiaquine over 3 days have been the first-line treatments for uncomplicated 
malaria and P. falciparum malaria; severe cases are treated with either parenteral 
artesunate, amodiaquine or quinine. Treatment failures are treated with quinine. 
Other malaria control strategies are the free distribution of ITNs/LLINs to all age 
groups since 2009 (World Health Organization, 2015a). 58 million LLINs were 
distributed between 2009 and 2013 through mass distribution campaigns, antenatal 
clinics, immunisation clinics and other channels. The national average for household 
ownership of at least one ITN is 42% with wide within-country variations. IRS has 
been recommended since 2007 however, the use of DDT is not authorised. In 2010, 
IRS was implemented in 7 States (21 LGAs) with support from the World Bank 
Malaria Booster Programme (Federal Ministry of Health, 2015).  Larval source 
management (LSM) has been incorporated as a component of integrated vector 
management within the last two years. There is no systematic coordination of 
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insecticide resistance monitoring at the national level. There is reported resistance to 
all four classes of insecticide in An. coluzzii and An. gambiae s.l. (World Health 
Organization, 2015a). 
Nigeria adopted Focused Antenatal Care (FANC) since 2004 with a view to 
drastically reduce the burden of malaria. FANC provides the most practical platform 
for the delivery of these interventions. The key interventions provided at the ANC for 
the prevention of malaria in pregnancy include administration of SP for intermittent 
preventive treatment (IPT) under the direct supervision of skilled service providers, 
distribution of LLINs, and appropriate case management through prompt diagnosis 
and effective treatment with recommended medicines. The implementation of FANC 
in Nigeria recommends that pregnant women should make at least, four visits; within 
16 weeks or when the woman first thinks she is pregnant, at 20-24 weeks or at least 
once in the second trimester, at 28-32 weeks and at 36 weeks or later. FANC 
encourages expectant mothers to make unscheduled visits whenever they 
experienced danger/warning signs in the course of pregnancy. 
Though the provision of malaria preventive services in pregnancy have been free in 
all public facilities, across the country, the utilisation has remained low due to the 
consistently low antenatal attendance, especially in some states in northern Nigeria 
where ANC attendance is still less than 30% (NDHS, 2014). The 2008 NDHS 
showed an average of 43.7% and 76.9% ANC attendance by rural and urban 
dwellers respectively. This improved slightly to 46.5% and 86.0% in 2013. This 
makes the administration of the intervention difficult in higher prevalence rural areas 
as it is primarily facility based at present and requires supervision by skilled health 
care providers. However, community-based strategies are being developed (Federal 
Ministry of Health, 2015). 
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3 METHODS 
3.1 OVERALL DESIGN 
An individually randomised, two-arm, open, parallel group, non-inferiority pragmatic 
trial was undertaken. The trial investigated whether screening for malaria with a rapid 
diagnostic test and treating women with that test positive for malaria with artemether-
lumefantrine was not inferior to intermittent preventive treatment with sulfadoxine-
pyrimethamine in the prevention of anaemia in pregnancy. Eligible and consenting 
pregnant women were randomly assigned (1:1) to one of the two study arms: 
i)  presumptive treatment with sulfadoxine-pyrimethamine (SP)-IPTp plus 
LLIN or  
ii) malaria screening and treatment with artemether-lumefantrine (AL) plus 
LLIN . 
Figure 3.1 shows the study plan for the trial including blood draws and timing of visits 
 
After the begining of the 2nd trimester
PREGNANCY
LLIN
Time at risk for maternal clinical malaria during pregnancy
.... during postpartum period
1st
dose
2nd
dose
Recruitment
Delivery
at least
1 month
Up to 6 
weeks after
delivery
Blood draws for parasitology/molecular techniques
17
 
Figure 3.1: Study plan. 
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3.2 RANDOMIZED CLINICAL TRIAL IN NIGERIA 
3.2.1 STUDY SITE 
The study was conducted in Calabar, Cross River State in South-East Nigeria 
(Figure 3.2) In the 2006 Population and Housing Census, Cross River state’s 
population was 2,868,966 made up of 1,492,465 males and 1,396,501 females. 
Using a growth rate of 3.4% the population of Cross River State in 2015 was 
3,908,692. The climate in Calabar is tropical-humid with wet and dry seasons, with 
average temperatures ranging between 15-30°C and the annual rainfall between 
1300-3000 mm. The vegetation in Calabar is mangrove swamp forest. Malaria 
transmission in this area is intense and perennial with a peak in the rainy season. P. 
falciparum is the predominant malaria-causing species (National Population 
Commission, 2012, World Health Organization, 2015a). 
Previous in vivo therapeutic efficacy studies have reported resistance to chloroquine 
and sulfadoxine/pyrimethamine in this area to be in the range of 30% to 80% 
(Ezedinachi et al., 1992, Federal Ministry of Health, 2002, Federal Ministry of Health, 
2005). An. gambiae is the predominant vector species. There is no information 
available on entomological inoculation rate (EIR) in the study area, but an EIR of 
about 259 infectious bites per person-year has been reported from Odukpani, a 
neighbouring area (Alaribe, 1999). National HIV prevalence is reported to be about 
3.4% with a prevalence of 5.5% in the region where the trial was conducted (Federal 
Ministry of Health, 2012). 
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Figure 3.2: Map of Calabar showing the study site with insert maps of Africa, 
Nigeria, and Cross River State 
The trial was conducted at the antenatal clinics of the General Hospital in Calabar, 
Nigeria. The General Hospital is the largest government-owned secondary health 
facility in the city and caters to the health needs of the majority of the inhabitants. 
Since August 2009, pregnant women and children under five years of age have 
received free medical care as part of a state-funded welfare program by the 
Government of Cross River State. The average annual antenatal clinic attendance at 
the hospital between 2013 and 2015 was 16,550; with an average of 3,100 births in 
the hospital annually (Ekpo A. personal communication). In the study area, the 
proportion of births attended by unskilled personnel has been estimated to be about 
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85% (Etuk et al., 2000, Etuk and Etuk, 2001). Additionally, only about 15% of births 
take place in health facilities in a health demographic and surveillance site 15 km 
from the study site (Enang, et al., 2013). 
3.2.2 RECRUITMENT OF PARTICIPANTS 
The study population included pregnant women of all parities who presented at the 
antenatal clinics at their first booking. Women were screened for eligibility and invited 
to participate in the study if they met all of the inclusion criteria. 
Inclusion criteria: pregnant with a gestational age of 16 to 24 weeks at their first 
booking; willing to have a supervised delivery; and permanent residence within 
Calabar and its environs.  
Exclusion criteria: a prior dose of IPTp-SP, a haemoglobin concentration < 6 g/dl, a 
history of sensitivity to SP, lumefantrine or an artemisinin. Other exclusion criteria 
were any illness requiring hospital admission (including severe malaria as defined by 
WHO), known HIV infection, known G6PD deficiency, past obstetric and medical 
history that would adversely affect the evaluation of outcomes and an unwillingness 
to participate in the study. 
3.2.3 RANDOMIZATION AND BASELINE EVALUATION 
After written informed consent had been obtained, eligible women were randomised 
to one of the two treatment groups. An allocation sequence was generated with 
STATA by a statistician who did not participate in the study. Women were randomly 
allocated to either of the two treatment groups in permuted blocks of ten. This 
randomly generated assignment to trial arms was printed and cut into slips which 
were sealed in opaque envelopes according to their blocks of 10.  During enrolment, 
an eligible pregnant woman was asked by a designated study nurse to pick a slip 
from the sealed envelope. The treatment group printed on each slip indicated the 
treatment arm to which the women belonged. Another opaque envelope was opened 
by the designated nurse only when the contents of the previous one had been 
exhausted. The study arm women belonged to was not identifiable by the study 
identification numbers given to them.  Also, the Principal Investigator and outcome 
assessors (midwives and microscopist were blinded to the randomisation process 
and treatment allocation to prevent bias in outcome assessment. Women who 
53 
 
declined to participate in the trial were treated with the routine standard of care, 
IPTp-SP according to the national guidelines. At the enrolment visit, a finger prick 
blood sample was obtained for measurement of haemoglobin concentration, 
preparation of blood films (thick and thin smears) for malaria parasite counts and 
preparation of dried blood spots (DBS) on filter paper. 
3.3 DESCRIPTION OF THE INTERVENTION 
3.3.1 INTERMITTENT SCREENING AND TREATMENT WITH AL 
Pregnant women were screened for malaria infection with malaria RDT (SD Bioline 
Malaria Ag P.f/Pan RDT kit, a Histidine-Rich Protein-2 (HRP-II) antigen and pLDH 
(Pan) antigen test, Standard Diagnostics, Inc.) at scheduled ANC visits. The test kits 
were purchased from the licensed local distributors of the product (Codix Pharma 
Limited Nigeria).  If the study women tested positive by RDT, they were treated with 
AL (20 mg artemether/ 120 mg lumefantrine) given as a 6-dose course, administered 
twice daily for three days). Study women were advised on the time and mode of 
administration for the three days treatment taken at home unobserved. 
3.3.2 INTERMITTENT PREVENTIVE TREATMENT WITH SP 
Women in the IPTp-SP arm received a single dose (3 tablets of 500mg sulfadoxine 
and 25mg pyrimethamine each) at enrolment (Visit 1) and the following visit (Visit 2) 
at least one month apart. Table 3.1 shows a summary of the drugs used for the 
intervention. 
Table 3.1: Summary of the intervention drugs. 
Study drug Manufacturer Drug formulation Dosing schedule 
Sulfadoxine-
pyrimethamine 
(Laridox®) 
IPCA Laboratories Ltd, 
India  
Tablet 1500 mg + 75 
mg  
Single dose 
Artemether-lumefantrine 
(Coartem®) 
Novartis Pharma, 
Switzerland  
20 mg +  120 mg Daily for 3 days 
 
3.3.3 ADDITIONAL INTERVENTIONS 
All study women received a long-lasting insecticidal net (LLIN) which they were 
encouraged to use throughout the pregnancy. Also, they received the routine 
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supplement of folic acid (4mg) and ferrous sulphate (200 mg) tablets usually 
provided at ANC in Nigeria based on national guidelines. HIV screening was offered 
to all study women in the context of the routine antenatal services recommended in 
Nigeria with an option for treatment, but the results of HIV screening were not 
available to the study team at the time of enrolment. 
3.3.4 FOLLOW-UP 
Study participants were asked to return to the clinic for follow-up antenatal care at 
which either IPTp-SP or screening with RDTs was given at 24, 32 and 36 weeks of 
gestation. At the next two follow-up visits (24 and 32 weeks of gestation), women in 
the IPTp-SP treatment group received SP while women in the ISTp-AL group were 
screened with the RDT and, if positive, treated with AL. As part of adverse event 
monitoring, all women were followed-up on the phone by a trained trial team member 
to record any complaints that the women might have a week after each scheduled 
antenatal visit. Study women were also provided with a mobile phone number which 
they could call to arrange unscheduled visits.  A team of nurses and lab scientists 
were dedicated to follow-up of women who did not present for delivery at the General 
Hospital within 2-3 weeks of the estimated delivery date to establish the outcome of 
the pregnancy. 
3.4 MALARIA DIAGNOSTICS 
3.4.1 MALARIA MICROSCOPY 
Microscopy blood smears were obtained at enrolment, the second follow-up visit, 
whenever a malaria infection was suspected, before delivery (36 to 40 weeks 
gestation) and at the postpartum visit (6 weeks post-delivery). At each of these time 
points, two thick and one thin film was prepared. Thick and thin smears were 
prepared for the estimation of asexual parasite density and to identify parasite 
species, respectively.   Clean frosted microscope slides were used to prepare blood 
smear, and these were stained with Giemsa (pH 7.2) using WHO procedures (World 
Health Organization, 2010b). Thick smear slides were rapidly stained for 15 minutes 
with 10% Giemsa stain. Second slides taken from study subjects were stained for 
about 30-45 minutes with 3% Giemsa stain. Slides were placed on wooden slide 
racks to dry and transferred to plastic slide boxes for safe handling and storage. An 
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experienced microscopist, blinded to trial group assignment, read all the blood films 
and calculated parasite density against 200 leucocytes in thick blood smears. A thick 
blood film was declared negative only after examination of 100 high power fields 
(HPF). 
3.4.2 RAPID DIAGNOSTIC TESTS 
Histidine-Rich Protein-2 (HRP-II) antigen and pLDH (Pan) antigen RDT kit (SD 
BIOLINE Malaria Ag P.f/Pan test, Standard Diagnostics, Inc.) was used for 
diagnostic confirmation of malaria in all patients in the ISTp-AL arm. The SD 
BIOLINE Malaria Ag P.f/Pan test is a qualitative and differential test for the detection 
of HRP-II antigen of P. falciparum and  plasmodium lactate dehydrogenase (pLDH) 
of Plasmodium species in human whole blood. About 5μl of whole blood was added 
to the well of the RDT kit, and two drops of the assay buffer were added to the well. 
The result was interpreted within 20 minutes based on the indication of the bands 
presented. The test kits were stored according to manufacturer’s instructions, and 
the viability of the kits was tested monthly using positive test controls obtained from 
the manufacturer. The tests were performed and interpreted by the trial team 
following the manufacturer’s instructions. 
3.5 EVALUATION OF HAEMOGLOBIN CONCENTRATION 
At enrolment and subsequent second and third follow-up visits, maternal 
haemoglobin concentration (Hb) was determined in finger prick blood using a 
HemoCue analyser (HemoCue Hb 301, HemoCue Ltd, United Kingdom) at the 
General Hospital Calabar. One microcuvette preparation was analysed per patient 
from a single blood specimen. Laboratory personnel collecting and analysing blood 
samples were trained for one day on machine operation before the actual data 
collection. Microcuvettes were kept free of moisture while microcuvette containers 
were stored at room temperature and kept away from heat or direct sunlight.  The 
microcuvette holder was cleaned at the end of each day’s work with an alcohol 
swab. The machine was always checked before use according to manufacturer’s 
instructions. 
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3.6 DETERMINATION OF BIRTHWEIGHT AND PREGNANCY-RELATED OUTCOMES 
For women who delivered at the hospital, birth weight was recorded by a midwife 
who was blinded to the treatment group of the woman whom she was attending. 
Women who delivered at home were traced by a follow-up team (made up of a lab 
scientist, trained community health worker and study nurse) within 6 days of delivery 
and the infant’s weight was measured.  The occurrence of miscarriages, stillbirths, 
neonatal deaths and the presence of congenital abnormalities were recorded by 
midwives. WHO definitions of miscarriage, stillbirth, and neonatal deaths were used 
for this trial. A miscarriage was defined as the premature loss of a foetus up to 23 
weeks of pregnancy and weighing up to 500 g while a stillbirth was defined as a 
baby born with no sign of life at or after 28 weeks’ gestation. Neonatal death was 
defined as a death occurring during the first 28 days of life (0-27 days). 
3.7 PLACENTAL MALARIA 
Immediately after delivery, the paracentric side of the maternal placenta was cleaned 
with sterile cotton wool and incised with a scalpel blade as previously described 
(Sowunmi et al., 1996). Two drops of blood collected by aspiration through a Pasteur 
pipette were used to prepare a thick blood smear and a blood spot on commercially 
available filter paper (Whatman 3MM, GE Healthcare Life Sciences, USA). The thick 
smears and blood spots were air-dried and stained with 4% Giemsa. An experienced 
microscopist immediately examined the stained smears by light microscopy to detect 
asexual forms of P. falciparum malaria parasites. 
3.8 DRIED BLOOD SPOT SAMPLES 
Three drops of peripheral blood (measured with 25µl pipette) were collected by 
finger prick and transferred onto commercially available filter paper (Whatman 3MM, 
GE Healthcare Life Sciences, USA). A sample was collected at each scheduled visit 
(V1, V2, and V3) before delivery. One blood spot was for DNA extraction, the second 
for RNA extraction and the third was a spare one. These filter papers were air dried 
for 3 hours and packed into small plastic bags with desiccant (silica gel). Dried blood 
spot (DBS) samples on filter paper were shipped to the Tropical Institute, Munich. 
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For pregnant women with malaria parasitaemia at any of these three visits, genomic 
DNA was subsequently extracted from the DBS on the filter paper using QIAamp® 
DNA Blood Mini kit (Qiagen, Krefeld, Germany), following manufacturer’s protocol. 
Species differentiation was then undertaken through the amplification of Plasmodium 
small subunit ribosomal RNA using nested PCR methods (Snounou et al., 1993, 
Schoone et al., 2000). 
3.9 SUB-STUDIES: LABORATORY PROCEDURES 
3.9.1 GENOTYPING PROCEDURES AND ANALYSIS OF dhfr AND dhps GENES 
Molecular genotyping was performed only on dried blood spot filter paper samples 
from pregnant women with a positive microscopy blood slide. P. falciparum parasites 
were genotyped for mutations in the dihydrofolate reductase (dhfr) and dihydrofolate 
synthase (dhps) genes by PCR-restriction fragment length polymorphism (PCR-
RFLP). Mutations were investigated at codons 51, 59, 108 and 164 of the Pfdhfr 
gene and codons 436, 437, 540, 581 and 613 of the Pfdhps gene as previously 
described (Duraisingh et al., 1998). Analysis of mutation at codons 51, 59, 108,164, 
436, 437, 540, 581 and 613 was performed using the following enzymes: Tsp509I, 
XmnI, AluI, DrapI, MspA1I, AvaII, FokI, BstUI, and RSaI respectively. They were 
subjected to 2.0% agarose gel electrophoresis and visualised under UV light. 
Amplified and digested products were compared with those of reference isolates. 
Isolates with mixed dhfr/dhps alleles comprising both wild-type and mutated alleles 
were categorised as mutants. 
3.9.2 MOLECULAR QUANTIFICATION OF SUB-MICROSCOPIC GAMETOCYTAEMIA (QT-
NASBA) 
Several antimalarials including SP have been shown to lead to the proliferation of 
gametocytes. This sub-study sought to quantify sub-microscopic gametocytaemia 
using real-time quantitative nucleic acid sequence-based amplification. This section 
describes the methods employed in the molecular quantification of gametocytaemia. 
The methods used for the QT-NASBA were as previously described (Pritsch et al., 
2012). 
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Specimen collection 
Finger prick DBS filter paper and thick film samples of study women who were 
positive for malaria by microscopy were chosen for the analysis. The samples were 
collected between March and August 2014 at the General Hospital. The finger prick 
DBS were of a sample volume of 25µl measured with a pipette and 25µl pipette tips. 
After air-drying, all samples were individually sealed in labelled plastic bags and 
stored with desiccant (silica gel). The samples had been stored for 1-3 weeks at 
room temperature and then shipped to Munich, Germany and subsequently stored at 
-20oC until ribonucleic acid (RNA) extraction and then quantitative nucleic acid 
sequence based amplification (QT-NASBA) was performed.  
RNA extraction 
For analysis, the samples containing 25 μL of finger-prick blood were cut out of the 
filter paper with heat sterilised scissors maintaining a distance of approximately 3 
mm to the border of the sample. The spots were subsequently soaked in 2 ml 
NucliSens® easyMAG® (bioMérieux, Lyon, France) lysis buffer containing 
guanidium isothiocyanate (GuSCN) and rocked at 150 rotations per minute (rpm) for 
30 minutes at room temperature. The solution was then centrifuged at 1,500 g for 5 
minutes, and the filter paper removed. 50 μL of silica particle solution (bioMérieux, 
Lyon, France) was added and then the RNA extraction method originally described 
by Boom et al. (Boom et al., 1990) was performed. Subsequently, nucleic acids were 
eluted from the silica with 30 μL elution buffer provided by the manufacturer. 
For each extraction, a negative control of Plasmodium-negative full blood spotted on 
filter paper and a positive control of Plasmodium-spiked (NF54 strain) full blood 
spotted on filter paper was used. After extraction, the samples were either stored at -
80°C for a maximum of 24 hours or immediately analysed by real-time  QT-NASBA 
technology using a previously described primer and beacon mix (Pritsch et al., 
2012). 
 
Real-time quantitative nucleic acid sequence-based amplification (QT-NASBA) 
Mature P. falciparum gametocytes were quantified using Pfs25 mRNA QT-NASBA 
(Schneider et al. 2006) as it is expressed only in stage V gametocytes. For Pfs25 
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mRNA, the forward primer was: 5’-GAC TGTAAA TAA ACC ATG TGG AGA-3’; the 
reverse primer was: 5’-AAT TCT AAT ACG ACT CAC TAT AGG GAG AAG GCA 
TTT ACC GTT ACC ACA AGT TA-3’. Pfs25 molecular beacon probe was 5’-
TexasRed-CGA TCG CCG TTT CAT ACG CTT GTA ACG ATC G-DABSYL-3. 
Briefly, real-time QT-NASBA for Pfs25 mRNA was performed using Nuclisens® 
EasyQ® Basic kit (bioMérieux, Lyon, France) according to the manufacturer’s 
manual at a KCl concentration of 80nM. The reaction mixture including reverse and 
forward primers and RNA eluate was incubated at 65oC for five minutes and 
subsequently at 41oC for 5 minutes.  
Before isothermal amplification at 41oC, 5 µl of Nuclisens enzyme mixture (AMV-RT, 
T7 RNA polymerase,  and RNAse H) was added to a total reaction volume of 20 µl 
and real-time amplification allowed for 90 minutes.  
Samples were also analysed in duplicate and considered positive when the time-
point of amplification at which the fluorescence detecting target amplicons (time to 
positivity = TTP) exceeded the mean fluorescence of three negative controls plus 20 
standard deviations (SD) as previously described (Schneider et al., 2004). 
3.10 DEFINITION OF OUTCOMES 
3.10.1 ANAEMIA 
Severe and moderate anaemia in this study was defined as pregnant women with a 
haemoglobin level less than 8g/dL and less than 11g/dL respectively. 
3.10.2 LOW BIRTH WEIGHT 
Low birth weight (LBW) was defined as a birth weight of a liveborn infant of less than 
2,500 g. 
3.10.3 ASYMPTOMATIC MALARIA PARASITAEMIA 
Asymptomatic malaria parasitaemia was defined as malaria infection confirmed by 
light microscopy without any clinical symptoms. 
3.10.4 CLINICAL MALARIA 
Clinical malaria was defined as the presence of clinical symptoms in addition to 
malaria parasitaemia confirmed by light microscopy. 
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3.10.5 PERINATAL DEATH 
Perinatal death was defined as the number of stillbirths and deaths in the first week 
of life. The perinatal period begins at 22 completed weeks of gestation and ends 
seven completed days after birth. 
3.10.6 ADVERSE EFFECT 
Any untoward medical incident in a patient or clinical investigation subject, 
temporarily associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. This also includes failure to produce 
expected benefits, abuse or misuse. 
3.10.7 SEVERE ADVERSE EVENT 
A serious adverse event is any untoward medical occurrence that, at any dose: 
a. Results in death. 
b. Can be considered life threatening (i.e. an event in which the subject was at 
risk of death at the time of the event). 
c. May requires hospitalisation or prolongation of existing hospitalisation. 
d. Results in disability/ incapacity. 
e. Results in congenital anomaly/birth defect. 
f. Additionally, a haemoglobin value of ≤ 5 g/dl in any pregnant woman was 
considered a serious adverse event. 
3.11 PARTICIPANT WITHDRAWAL 
Patients were withdrawn if they withdrew their informed consent or if they left the 
study area permanently. 
3.12 ETHICAL CONSIDERATIONS 
Participation in the study was voluntary; subjects were free to withdraw from the 
study at any time, and this did not affect their access to quality care. Information 
obtained from all subjects was treated as confidential. The trial was conducted under 
the provisions of the Declaration of Helsinki and in accordance with Good Clinical 
Practices guidelines set up by the WHO and by the International Conference on 
Harmonization. 
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The purpose of the study, the procedures to be followed, and the risks and benefits 
of participation were explained to all participants. Information sheets and consent 
forms were provided to them for their review. Each participant was asked to sign an 
informed consent to participate in the research study.  
The study proposal and informed consent forms were reviewed and approved by two 
ethics committees: the Cross River Health Research Ethics Committee, Calabar, 
Nigeria and the Ethics Board of the Medical Center of LMU, Munich, Germany.  The 
trial was registered prior to the enrolment of participants in the Pan African Clinical 
Trials Registry (PACTR201308000543272). 
3.13 SAMPLE SIZE 
The sample size was calculated based on the assumption that the prevalence of 
severe anaemia in the third trimester of pregnancy in the IPTp-SP arm of the study 
would be at least 3% based on findings from a previous study undertaken in Ghana 
(Tagbor et al., 2010). Due to widespread resistance to SP, it was hypothesised that 
the prevalence of severe anaemia would be significantly lower in the LLIN plus 
intermittent malaria screening with AL (ISTp-AL arm) compared to the LLIN plus 
intermittent preventive treatment with SP (IPTp-SP). To establish that AL-IST was 
not inferior to IPTp-SP it was necessary to show that the differences in the proportion 
of women with severe anaemia between the ISTp-AL and IPTp-SP arms would not 
be more than 5%, differences which would be of clinical and public health 
importance. 
Thus, if there were truly no difference between the prevalence of severe anaemia in 
the conventional IPTp-SP and ISTp-AL arm, then 366 participants (183 per arm) 
were required to detect a 5% difference between the two study arms at 95% 
significance with 80% power. This meant that if there was truly no difference 
between IPTp-SP and ISTp-AL, then 366 patients were required to be 80% sure that 
the upper limit of a 95% two-sided confidence interval would exclude a difference in 
favour of the IPTp-SP group of more than 5%. With 20% adjustment for attrition, a 
sample size of 460 pregnant women (230 per arm) was adequate. Thus a sample 
size of 460 (230 per arm) was sufficient to detect any differences in the prevalence 
of severe anaemia between the two arms. 460 pregnant women (230 IPTp-SP: 230 
62 
 
ISTp-AL) were randomised, allowing for a 20% withdrawal/loss to follow-up and a 
non-inferiority margin of 5%, to yield 366 evaluable pregnant women for the primary 
outcome (183 IPTp-SP: 183 ISTp-AL). 
3.14 STATISTICAL METHODS 
Stata version 12 (StataCorp, College Station, Texas) was used for data analyses. 
The primary objective of the study was to demonstrate that the risk of third-trimester 
severe anaemia (Hb ≤ 8 g/dl) in the ISTp-AL group was no more than 5% greater 
than in the IPTp-SP group. The secondary objectives were to demonstrate that the 
risks of low birth weight, neonatal and maternal mortality, spontaneous abortions, 
intrauterine deaths and stillbirths, were not significantly higher in women in the ISTp-
AL group than in women who received IPTp-SP. The main analysis of primary and 
secondary outcomes was according-to-protocol (ATP). However, a modified 
intention-to-treat (mITT) analysis was also undertaken. In the ATP analysis, only 
data from women who remained within their randomization group and had a record 
for the primary outcome were included. This implied that study women had to have 
received two courses of SP (IPTp-SP arm) or been screened twice using an RDT at 
scheduled visits (ISTp-AL arm) and in addition, have a measurement for the primary 
outcome (haemoglobin level at 36-40 weeks gestation) to be eligible for inclusion 
into the ATP analysis.  
In the mITT analysis, data from women who received an initial treatment of IPTp or 
had an initial screening test done and had a record for the primary outcome or the 
outcome of interest recorded. This implied that study women had to have received 
one course of SP (IPTp-SP arm) or been screened once using an RDT at scheduled 
visits (ISTp-AL arm) and in addition, have a measurement for the primary outcome or 
outcome of interest.  
The proportion of ATP and mITT populations experiencing the primary and 
secondary outcomes in both trial arms, and the associated 2-sided 95% CI for the 
difference, was estimated using the generalised linear model. To declare non-
inferiority, the upper boundary of the 2-sided 95% CI for the estimated treatment 
effect (i.e. risk difference) had to be below the pre-defined non-inferiority margin (∆) 
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of 5% at a significance level of 0.05. We controlled for gravidity, gestational age at 
enrolment, baseline anaemia and parasitaemia using binomial regression. 
Only birth weights from singleton pregnancies of live births ≥22 weeks’ gestation with 
no congenital abnormality and measured within six days of delivery were included in 
birth weight analyses. 
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4 RESULTS 
4.1 OVERVIEW 
The preceding chapter 3 described the methods used in the clinical trial and the 
sulfadoxine-pyrimethamine molecular markers study in Nigeria which led to key 
findings presented in this chapter: the trial profile, the impact of ISTp on malaria-
related morbidity, and safety. The prevalence of molecular markers of SP resistance 
and gametocytes determined by QT-NASBA are also presented in this chapter. 
 
4.2 TRIAL PROFILE 
A total of 593 potentially eligible women were screened starting in October 2013 and 
460 women were included in the trial while 133 women were not included because 
they did not meet the inclusion criteria (41) or declined to participate in the study 
(92).   
The 460 pregnant eligible women were randomised, 230 to IPTp-SP and 230 to 
ISTp-AL. One allocation error occurred, a woman previously enrolled in the trial was 
randomised a second time. Thus leaving 459 women who completed the first visit 
(i.e. received an initial treatment of IPTp with SP or had had an initial screening test 
done); 229 in the IPTp-SP group and 230 in the ISTp-AL group.  At the end of follow-
up, 239 (52.1 %) evaluable records for third-trimester haemoglobin concentration 
and 329 (71.7 %) records for birth weight were available. Three women withdrew 
from the study (two in the IPTp-SP group and one in the ISTp-AL group). The 
distribution of the randomised pregnant women is summarised in Figure 4.1. 
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Figure 4.1: Trial profile showing enrolment and follow-up status of study women. 
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4.3 BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS 
Baseline characteristics of study women in both treatment groups were very similar 
at enrolment and are shown in Table 4.1. About three-quarters of the study women 
in both arms were aged between 13 and 30 years with an overall mean age of 28.2 
years. All study women had some level of formal education, and over 90% of them 
had been educated up to at least secondary school level.  
The majority of the study women were students in tertiary institutions. Only 22% of 
the study women were salary workers comprised mainly of civil servants and 
teachers. 57% of the study women’s households already owned a bed net at 
enrolment. However self-reported bed net use the night preceding enrolment was 
about 15%. Forty-seven percent of study women were primigravidae, and 29% were 
multigravidae. 
Overall, 1.1% (5/459) of women had baseline severe anaemia (i.e. a haemoglobin 
(Hb) concentration below 8 g/dl). The overall mean baseline haemoglobin 
concentration was 11.5 g/dl. Asymptomatic parasitaemia as determined by 
microscopy was present in 7% (32/459) of study women overall with parasite 
densities less than 500/mL in about 37.5% (12/32). The prevalence of malaria 
infection on presentation at the antenatal clinic in women in the ISTp-AL arm as 
determined by the SD Bioline® rapid diagnostic test was 5.7% (RDTs were not done 
in women in the IPTp-SP arm). Baseline anaemia was significantly associated with 
asymptomatic malaria parasitaemia (p <0.0001). P. falciparum was the prevalent 
malaria species. One mixed infection of P. malariae and P. falciparum was observed. 
The overall prevalence of HIV in pregnant women who were enrolled during the 
period of the trial was 1.3%. 
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Table 4.1: Comparison of demographic and baseline characteristics of study women 
 Control 
IPTp-SP 
Intervention 
ISTp-AL 
All participants 
 (N=229) (N=230) (N=459) 
 N (%) n (%) n (%) 
Age (years)       
≤ 25 58 25.3 76 33 135 29.4 
26-30 103 45 86 37.4 189 41.0 
≥ 31 68 29.7 68 29.6 136 29.6 
Mean (SD) 28.4 4.6 27.9 5.4 28.2 5.0 
Median (IQR) 28 6 28 7 28 6 
       
Educational attainment       
Primary 7 3.1 6 2.6 13 2.8 
Secondary 96 41.9 99 43 195 42.5 
Tertiary 126 55 125 54.4 251 54.7 
       
Occupation       
None 10 4.4 21 9.1 31 6.8 
Student 49 21.4 46 20 95 20.6 
Housewife 26 11.4 24 10.4 50 10.9 
Small business owner 92 40.1 90 39.1 182 39.7 
Salary worker 52 22.7 49 21.3 101 22 
       
Gravidity       
Primagravidae 107 46.7 109 47.4 216 47.1 
Secundigravidae 68 29.7 69 30.0 137 29.8 
Multigravidae 54 23.6 52 22.6 106 23.1 
       
Ownership of bed net       
No 99 43.2 108 47 207 45.1 
Yes 130 56.8 122 53 252 54.9 
       
Slept under bed net (previous 
night) 
      
No 197 86.0 195 84.8 392 85.4 
Yes 32 14.0 35 15.2 67 14.6 
       
Baseline Parasitaemia       
No 212 92.6 215 93.5 427 93.0 
Yes 17 7.4 15 6.5 32 7.0 
Parasite density  
Geometric mean [95% CI] 
 
954.8  
 
 
[490.4 -1859.3] 
 
951 
 
[452.5 -
1998.5] 
 
953  
 
[597.3 -
1520.6] 
Haemoglobin (g/dl)       
11 and above 135 59 165 71.7 300 65.4 
8-10.9 92 40.2 62 27.0 154 33.5 
<8 2 0.8 3 1.3 5 1.1 
Mean (SD) 11.4 1.4 11.6 1.3 11.5 1.4 
Median (IQR) 11.3 1.8 11.6 1.4 11.5 1.6 
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4.4 STUDY OUTCOMES-ACCORDING TO PROTOCOL (ATP) ANALYSIS  
4.4.1 ANAEMIA    
At 36–40 weeks of gestation (third trimester before delivery) the overall prevalence 
of the primary outcome, severe anaemia (Hb<8 g/dl) was 0.84% and similar in both 
treatment groups (p=0.145). The prevalence of moderate anaemia (Hb 8 -10.9 g/dl) 
was 27.7% (Table 4.2) and was similar in both treatment groups (p=0.204). 
The mean haemoglobin concentration (Hb) of all women between 36 and 40 weeks 
of gestation was 11.5 g/dl. The mean Hb concentration in the ISTp-AL and IPTp-SP 
groups were 11.7g/dl and 11.4 g/dl respectively. However, this difference was not 
statistically significant (p= 0.073). There was a non-significant increase in mean 
haemoglobin concentration of 0.05 g/dl at 36-40 weeks of gestation over the 
baseline haemoglobin concentration (Figure 4.2).  There was no significant 
difference in haemoglobin concentration during the course of pregnancy between the 
two trial arms. 
Table 4.2: Comparison of the main outcomes in women enrolled in IPTp-SP and 
ISTp-AL arms (ATP analysis). 
 
Outcome All  
participants 
Control  
(IPTp-SP) 
Intervention 
 (ISTp-AL) 
p-value 
Anaemia     
Severe anaemia (Hb< 8g/dl) 2/238 (0.84) 2/114 (1.7) 0/124 (0) 0.145 
Moderate anaemia (Hb 8-10.9 g/dl) 66/238 (27.7) 36/114 (31.6) 30/124 (24.2) 0.203 
Hb ≥ 11 g/dl 170/238 (71.4) 76/114 (66.7) 94/124 (75.8) 0.121 
Mean haemoglobin g/dl (SD)  11.4 (1.3) 11.7 (1.2) 0.073 
 
Birth weight 
    
Normal (≥ 2.5kg) 269/286 (94.1) 130/139 (93.5) 139/147 ( 94.6)  
Low (< 2.5kg) 17/286 (5.9) 9/139 ( 6.5) 8/147 (5.4 ) 0.694 
Mean (SD) 3.19 (0.5) 3.21 (0.51) 3.18 (0.54) 0.630 
Median (IQR) 3.20 (2.5) 3.20 (0.6) 3.20 (0.6)  
 
Parasitaemia 
    
Peripheral blood  
(light microscopy) 
All infections 
 
 
4/208 (1.9) 
 
 
4/96 (4.2) 
 
 
0/112 (0) 
 
 
0.029 
SD: standard deviation IQR: inter-quartile range 
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The risk of third-trimester severe anaemia (Hb <8g/dl) did not differ significantly 
between both treatment groups (RD -1.75% [95% CI; -4.16 to 0.66]. The upper 
boundary of the 2-sided 95% CI for the risk difference estimated between the ISTp-
AL and IPTp-SP groups was below the non-inferiority margin of 5% set for third-
trimester severe anaemia. 
 
 
Figure 4.2: Variation of haemoglobin concentration between enrolment and third 
trimester (36 – 40 weeks gestation). 
The risk of anaemia (severe or moderate) did not differ significantly between both 
treatment groups (Table 4.2). Primigravidae women were significantly associated 
with a lower risk of anaemia compared to secundi- and multigravidae in univariate 
analysis. In a multivariate analysis, which adjusted for baseline anaemia, treatment 
group, maternal age, and baseline parasitaemia, primigravidae remained 
significantly associated with lower risk of anaemia in the third trimester (Table 4.3). 
The risk of moderate anaemia (<11g/dl) was not higher in the ISTp-AL group than in 
women who received IPTp-SP; (RD= -6.1% [95% CI; -17.9 to 5.8].  In the adjusted 
analysis, the risk difference was -5.4% [95% CI; -17.0 to 6.2]. All malaria infections 
were mild, and thus no study woman was admitted to hospital. 
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Table 4.3: Factors associated with third-trimester anaemia (<11g/dl) in study women 
(ATP analysis). 
 
 
Unadjusted 
Risk Ratio 
(95%CI)a p-
valueb 
Adjusted 
Risk 
Ratio 
(95%CI) p-value 
       
Treatment group 
ISTp-AL  
IPTp-SP 
 
 
0.83 
1 
 
0.57 to 1.20 
 
0.318 
 
0.81 
1 
 
0.57 to 1.17 
 
0.259 
Age category 
≤ 25 
26-30 
≥ 31 
 
1 
1.07 
1.31 
 
 
0.67 to 1.72 
0.81 to 2.12 
 
 
0.766 
0.279 
 
1 
0.95 
1.03 
 
 
0.59 to 1.52 
0.61 to 1.75 
 
 
0.824 
0.899 
Baseline 
parasitaemia 
Yes 
No 
 
 
1.49 
1 
 
 
0.90 to 2.45 
 
 
0.119 
 
 
1.46 
1 
 
 
0.89 to 2.41 
 
 
0.138 
Gravidity 
Primigravidae 
Secundigravidae 
Multigravidae 
 
0.57 
0.67 
1 
 
0.38 to 0.87 
0.42 to 1.08 
 
0.008 
0.104 
 
0.59 
0.66 
1 
 
0.37 to 0.93 
0.41 to 1.06 
 
0.024 
0.087 
CI: confidence interval  
a p ≤0.05 means observed differences between comparison groups is statistically significant or not significant if 
p>0.05. 
b Risk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and 
gravidity were included in the final model.  
4.4.2 BIRTH WEIGHT 
The overall prevalence of low birth weight was 5.9% in the study women and did not 
differ significantly between the two groups (p=0.694). However, the trial was not 
powered to investigate non-inferiority for this outcome (Table 4.2). The risk 
difference for low birthweight between the ISTp-AL and IPTp-SP arms was (RD -
1.03% [95% CI; -6.53 to 4.46]. In an adjusted analysis (Table 4.4) which controlled 
for maternal age, gravidity baseline anaemia and baseline parasitaemia, the risk 
difference for low birthweight was (RD -1.53% [95% CI; -1.54 to -1.15] and 
significantly lower in the ISTp-AL arm (p<0.0001). 
The risk of low birth weight did not differ significantly between the various age groups 
(Table 4.4). Baseline parasitaemia and gravidity were not significantly associated 
with low birth weight babies (Table 4.4). 
None of the study women with low birthweight babies had severe anaemia at 
enrollment. 
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Table 4.4: Factors associated with low birth weight of babies delivered by study 
women (ATP analysis). 
 Unadjusted 
Risk Ratio 
(95%CI) p-valuea Adjusted  
Risk Ratiob 
(95%CI) p-value 
Treatment group 
ISTp-AL 
IPTp-SP 
 
0.84 
1 
 
0.33 to 2.12 
 
0.712 
 
0.84 
1 
 
0.33 to 2.17 
 
0.72 
Age category (years) 
≤ 25 
26-30 
≥ 31 
 
1 
1.17 
1.08 
 
 
0.37 to 3.77 
0.30 to 3.86 
 
 
0.787 
0.911 
 
1 
1.43 
2.22 
 
 
0.44 to 4.59 
0.58 to 8.42 
 
 
0.548 
0.242 
Baseline parasitaemia 
Yes 
No 
 
1.46 
1 
 
0.35 to 5.99 
 
0.603 
 
1.62 
 
0.39 to 6.63 
 
0.505 
Baseline mild anaemia 
Yes 
No 
 
 
1.32 
1 
 
 
0.52 to 3.37 
 
 
0.558 
 
 
1.41 
 
 
0.53 to 3.70 
 
 
0.489 
Gravidity 
Primigravidae 
Secundigravidae 
Multigravidae 
 
3.18 
1.31 
1 
 
0.73 to 13.81 
0.23 to 7.65 
 
0.123 
0.761 
 
4.54 
1.44 
 
0.94 to 21.84 
0.24 to 8.69 
 
0.059 
0.694 
CI: confidence interval  
a p ≤0.05 means observed differences between comparison groups is statistically significant or not significant if 
p>0.05. 
b Risk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and 
mild anaemia, and gravidity were included in the final model.  
4.4.3 PERIPHERAL AND PLACENTAL MALARIA  
The prevalence of peripheral malaria (asymptomatic parasitaemia) among pregnant 
women at any time during the study was 9.2% in study women overall and was very 
similar in both treatment groups (p=0.80). 
The risk of malaria parasitaemia at 36 - 40 weeks was significantly higher in the 
IPTp-SP arm than in the ISTp-AL arm as shown in Table 4.2 (4.2% versus 0%, 
p=0.029). The risk difference for malaria parasitaemia between the ISTp-AL and 
IPTp-SP groups was RD -3.96% [95% CI -7.76 to -0.16]. One episode of illness 
associated with malaria parasitaemia was recorded in the IPTp-SP arm, during the 
course of the trial. In all, 533 RDT tests were done in women in the ISTp-AL 
treatment group of which 40 (7.5%) were positive and led to treatment. 
The prevalence of placental malaria at delivery as determined by microscopy was 
low with just one low-density infection identified from 46 (10%) samples collected 
from study women.  
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Between March and August 2014, 125 samples (106 enrollment samples and 19 
follow-up samples) were collected and analysed for Pfs25mRNA by QT-NASBA. 
Sample collection and analysis in Munich had to be stopped due to the Ebola crisis. 
Of these samples, 51 (40.8%) were from women in the IPTp-SP group while 74 
(59.2%) were from women in the ISTp-AL group (Table 4.5). Enrolment gametocyte 
prevalence was 0% (0/106) by microscopy and 2.8% (3/106) by QT-NASBA. The 
enrolment gametocyte prevalence by QT-NASBA in the IPTp-SP and ISTp-AL 
groups were 2.2% (1/45) and 3.3% (2/61) respectively but did not differ significantly 
between treatment groups (p=0.7358).  No gametocytes were detected by 
microscopy or QT-NASBA in the follow-up samples. 
Table 4.5: Gametocyte prevalence of Plasmodium falciparum by microscopy and 
QT-NASBA 
 Total IPTp-SP ISTp-AL p-value 
Enrolment 
n (%) 
    
Microscopy 0/106 (0) 0/45 (0) 0/61 (0) - 
QT-NASBA 3/106 (2.8) 1/45 (2.2) 2/61 (3.3) 0.7358 
Follow-up 
n (%) 
    
Microscopy 0/19 (0) 0/6 (0) 0/13 (0) - 
QT-NASBA 0/19 (0) 0/6 (0) 0/13 (0) - 
Total 125    
 
4.4.4 HAEMOGLOBIN LEVELS AND BIRTH WEIGHT OUTCOMES IN WOMEN WHO WERE RDT 
NEGATIVE THROUGHOUT THE TRIAL   
The risk of third-trimester anaemia (36-40 weeks gestation) and low birth weight in 
pregnant women who were RDT negative throughout pregnancy (received no 
antimalarial treatment) was not higher than in the IPTp-SP arm (Table 4.6)  
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Table 4.6: Anaemia before delivery (36-40 weeks) and birth weight by treatment 
group in RDT negative women 
Outcome According to Protocol Analysis 
Anaemia Control  
(IPTp-SP) 
Intervention  
(ISTp-AL) 
 
p-value 
Severe anaemia  
(Hb< 8g/dl) 
2/114 (1.7) 0/84 (0) 0.23 
 
0.229 
 
 
0.147 
Moderate anaemia  
(Hb 8-10.9 g/dl) 
36/114 (31.6) 20/84 (23.8) 
Hb ≥ 11 g/dl 76/114 (66.7) 64/84 (76.2) 
 
Mean haemoglobin g/dl (SD) 11.4 (1.3) 11.7 (1.17) 0.096 
Birth weight    
Normal (≥ 2.5kg) 130/139 (93.5) 62/65 (95.4) 0.591 
Low (< 2.5kg) 9/139 (6.5) 3/65 (4.6) 
Mean (SD) 3.21 (0.51) 3.23 (0.43) 0.753 
Median (IQR) 3.2 (0.6) 3.2 (0.5)  
4.5 STUDY OUTCOMES – MODIFIED INTENTION TO TREAT (mITT) ANALYSIS  
All the primary and secondary outcomes were also analysed using modified intention 
to treat (mITT) analysis with similar results to those of the ATP analysis. 
4.5.1 ANAEMIA  
The overall prevalence of third trimester (36-40 weeks) severe anaemia was 0.84% 
and not significantly different between both study groups (p=0.14). Similarly, there 
was no significant difference between study groups regarding the prevalence of 
moderate anaemia (Table 4.7). The overall mean haemoglobin concentration in the 
third trimester (36-40 weeks gestation) for study women was 11.5 g/dl. The average 
haemoglobin concentration in the ISTp-AL and IPTp-SP groups were 11.7g/dl and 
11.4 g/dl respectively. However, this difference was not statistically significant (p= 
0.076). 
The risk of third-trimester severe anaemia (Hb <8g/dl) did not differ significantly 
between both treatment groups (RD -1.74% [95% CI; -4.1 to 0.65]. The upper 
boundary of the 2-sided 95% CI for the risk difference estimated between the ISTp-
AL and IPTp-SP groups was below the non-inferiority margin of 5% set for third-
trimester severe anaemia as was the case in the ATP analysis. 
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Table 4.7: Comparison of the main outcomes in women enrolled in IPTp-SP and 
ISTp-AL arms (mITT analysis) 
Outcome  mITT analysis 
Anaemia Total IPTp-SP ISTp-AL p-value 
Severe anaemia (Hb< 8g/dl) 2/239 (0.84) 2/115 (1.7) 0/124 (0) 0.14 
Moderate anaemia (Hb 8-10.9 
g/dl) 
66/239 (27.6) 36/115 (31.3) 30/124 (24.2) 0.22 
 
Hb ≥ 11 g/dl 171/239 (71.5) 77/115 (67) 94/124 (75.8) 0.132 
Mean haemoglobin g/dl (SD) 11.5 (1.3) 11.4 (1.4) 11.7 (1.2) 0.076 
 
Birth weight 
    
Normal (≥ 2.5kg) 305/325 (93.8) 148/158 (93.7) 157/167 (94)  
0.898 
Low (< 2.5kg) 20/325 (6.2) 10/158 (6.3) 10/167 (6.0) 
Mean (SD) 3.2 (0.5) 3.21 (0.53) 3.17 (0.53) 0.497 
Median (IQR) 3.2 (0.4) 3.2 (0.6) 3.2 (0.6)  
 
Parasitaemia 
    
Peripheral blood  
(light microscopy) 
All infections 
 
 
4/213 (1.9) 
 
 
4/101 (4.0) 
 
 
0/112 (0) 
 
 
0.034 
 
Also, primigravidae women were significantly associated with a lower risk of anaemia 
compared to secundi- and multigravidae in univariate analysis (RR 0.57, 95% CI 
0.38 to 0.87). In a multivariate analysis, which adjusted for baseline anaemia, 
treatment group, maternal age, and baseline parasitaemia, primigravidae women 
were still associated with a significantly lower risk of anaemia in the third trimester 
(Table 4.8) 
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Table 4.8: Factors associated with third-trimester anaemia (<11g/dl) in study 
women (mITT analyses) 
 
 
Unadjusted 
Risk Ratio 
(95%CI)a p-
valueb 
Adjusted 
Risk Ratio 
(95%CI) p-value 
       
Treatment group 
ISTp-AL  
IPTp-SP 
 
 
0.83 
1 
 
0.58 to 1.21 
 
0.341 
 
0.82 
1 
 
0.57 to 1.17 
 
0.272 
Age category 
≤ 25 
26-30 
≥ 31 
 
1 
1.06 
1.31 
 
 
0.66 to 1.71 
0.81 to 2.12 
 
 
0.798 
0.279 
 
1 
0.94 
1.03 
 
 
0.58 to 1.05 
0.61 to 1.75 
 
 
0.785 
0.904 
Baseline 
parasitaemia 
Yes 
No 
 
1.49 
1 
 
0.91 to 2.46 
 
0.115 
 
1.45 
1 
 
0.89 to 2.43 
 
0.128 
Gravidity 
Primigravidae 
Secundigravidae 
Multigravidae 
 
0.57 
0.66 
1 
 
0.38 to 0.87 
0.41 to 1.07 
 
0.008 
0.092 
 
0.59 
0.65 
1 
 
0.37 to 0.93 
0.40 to 1.05 
 
0.024 
0.076 
CI: confidence interval 
a p ≤0.05 means observed differences between comparison groups is statistically significant or not significant if 
p>0.05. 
b Risk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and 
gravidity were included in the final model.  
 
The risk of moderate anaemia (<11g/dl) was no higher in the ISTp-AL group than in 
women who received IPTp-SP; (RD= -5.8% [95% CI; -17.6 to 6.1].  In the adjusted 
analysis, the risk difference was -5.5% [95% CI; -17.1 to 6.1]. Again these results are 
similar to those obtained in the ATP analyses. 
4.5.2 BIRTHWEIGHT 
The overall prevalence of low birth weight was 6.2% in the study women and did not 
differ significantly between the two groups (p=0.898, Table 4.7). However, the trial 
was not powered to investigate non-inferiority for this outcome. The risk of low birth 
weight in the ISTp-AL group was not significantly different from that in the IPTp-SP 
group (RR 0.95 [95% CI; 0.40 to 2.21], p=0.898.  In an adjusted analysis (Table 4.8) 
which controlled for maternal age, gravidity baseline parasitaemia and baseline 
anaemia the risk of low birth weight in the ISTp-AL group was not significantly 
different from that in the IPTp-SP group (RR 0.94 [95% CI; 0.40 to 2.25], p=0.896.  
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4.5.3 PERIPHERAL MALARIA 
The prevalence of peripheral malaria parasitaemia at 36-40 weeks gestation was 
1.9% in study women overall (Table 4.7). There was also significantly higher 
peripheral malaria parasitaemia in the IPTp-SP arm compared to the ISTp-AL arm 
(4% versus 0%, p=0.034).  
4.6 CLINICAL TOLERABILITY OF THE INTERVENTIONS  
4.6.1 MILD ADVERSE EVENTS  
All women were followed up for side effects after the enrolment visit. The most 
commonly reported mild adverse events were a headache, cough, catarrh, vomiting, 
and dizziness. These symptoms were not significantly different between both 
treatment groups.  However, women in the ISTp-AL arm complained of fever since 
their last antenatal clinic visit more frequently than in the IPTp-SP arm (p= 0.022) 
(Table 4.9). All malaria infections were mild, and thus no study woman was admitted 
to hospital. 
Table 4.9: Comparison of the number of women who experienced adverse events. 
  Total IPTp-SP ISTp-AL   
  n (%) n (%) n (%) p-value 
Headache 69 (15) 35 (15.3)  34 (14.8) 0.929  
Cough 40 (8.7) 23 (10) 17 (7.4) 0.323  
Catarrh 30 (6.5) 15 (6.6) 15 (6.5)  0.966 
Vomiting 16 (3.5) 7 (3.1) 9 (3.9)  0.641 
Dizziness 16 (3.5) 6 (2.6) 10 (4.3)  0.319 
Fever 12 (2.6) 2 (0.9) 10 (4.3)  0.022 
Body pain 9 (2.0) 5 (2.2) 4 (1.7) 0.699  
Itching 5 (1.1) 4 (1.7) 1 (0.4)  0.172 
Nausea 1 (0.2) 1 (0.4) -   0.337 
Rash 1 (0.2)  - 1 (0.4) 0.338  
Sleepiness 1 (0.2)  - 1 (0.4) 0.338  
 
4.6.2 SERIOUS ADVERSE EVENTS 
There was one maternal death in the IPTp-SP arm. No drug-related serious adverse events 
occurred during the trial. The prevalence of perinatal deaths was 6.2% and did not differ 
significantly between both trial groups (Table 4.10). Also, there were no statistically 
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significant differences in the risk of preterm deliveries and abortions between both study 
arms (Table 4.10).  
Table 4.10: Comparison of delivery outcomes for singleton births 
  Total 
n (%) 
IPTp-SP 
n (%) 
ISTp-AL 
n (%) 
p-value 
Term deliveries 389 (92.6) 191 (93.2) 198 (92.1)  
Preterm deliveries 1 (0.24) 1 (0.48) - 0.306 
Abortions 4 (0.95) 2 (0.96) 2 (0.93) 0.962 
Perinatal deaths 26 (6.2) 11 (5.36) 15 (6.97) 0.493 
*Outcome of pregnancy not determined for 39 study women who were lost to follow-up 
 
4.7 SULFADOXINE-PYRIMETHAMINE MOLECULAR MARKERS OF RESISTANCE 
To determine the prevalence of SP molecular resistance markers in P. falciparum 
isolates from pregnant women in Southeast Nigeria, DBS filter paper of women with 
positive peripheral malaria microscopy slide samples were analysed for Pfdhfr and 
Pfdhps genes. 
A total of 43 samples from 39 study women infected with P. falciparum based on 
microscopic examination of blood smear and nested PCR were included in the 
analysis of Pfdhfr mutations at codons 51, 59, 108, and 164, and Pfdhps mutations 
at codons 436, 437, 540, 581 and 613. The majority of study women (74.4%) were 
aged ≤30 years old, and 76.9% (30/39) of them did not use insecticide-treated bed 
nets the night before enrolment. 97.4% (38/39) of the patients had no fever. The 
mean Hb concentration was 10.1 ± 1.5 g/dl. The median parasite density was 776 
asexual parasite/μl with an interquartile range of 237–3248 asexual parasite/μl.  
Mutant alleles are presented in Table 4.11. Pfdhfr mutations were detected in 93% 
(40/43) of P. falciparum isolates for codons 51 (51I) and 59 (59R).  All isolates had 
mutant alleles for codon 108(108N).  No mutation was identified at codon 164. A 
single mutation in codon 108 (108N) in the Pfdhfr gene was detected in 7% (3/43) 
isolates.  
Pfdhps mutations were detected in 79% (34/43), and 95% (41/43) of the P. 
falciparum isolates for codons 436 and 437 respectively. No mutation was identified 
at codon 540. The prevalence of mutations at codons 581 and 613 was 69.8% each. 
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A single mutation in codon 437 in the Pfdhps gene was detected in 16.3% (7/43) 
isolates. There was no significant difference in the distribution of the mutant alleles 
between the IPTp-SP and ISTp-AL groups in the Pfdhfr and Pfdhps genes (Table 
4.11). 
Table 4.11: Proportion of SP molecular markers of resistance in both trial arms 
  IPTp-SP ISTp-AL Total  
(PCR positive)  23 20 43  
  Proportion (%) carrying the mutant alleles p-value 
Pfdhfr 51-Ile 22 (95.7) 18 (90) 40 (93) 0.464 
59-Arg 22 (95.7) 18 (90) 40 (93) 0.464 
108-Asn 23 (100) 20 (100) 43 (100) - 
164-Leu 0 (0) 0 (0) 0 (0) - 
Pfdhps 436-Ala 18 (78.3) 16 (80) 34 (79.1) 0.891 
437-Glu 23 (100) 18 (90) 41 (95.3) 0.120 
540-Gly 0 (0) 0 (0) 0 (0) - 
581-Gly 18 (78.3) 12 (60) 30 (69.8) 0.192 
613-Ser 18 (78.3) 12 (60) 30 (69.8) 0.192 
 
The prevalence of mutations in the Pfdhfr and Pfdhps genes was high at all visits as 
shown in Figure 4.3 and Figure 4.4. Even the baseline prevalence of Pfdhfr and 
Pfdhps resistance markers was above 70% in all P. falciparum isolates identified. 
 
 
Figure 4.3: Prevalence of Pfdhfr resistance markers by trial visit. 
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Figure 4.4: Prevalence of Pfdhps resistance markers by trial visit. 
Genotyping analysis was conducted based on sequences for Pfdhfr, Pfdhps, and 
combined Pfdhfr–Pfdhps genes. Single (NCNI) and triple (IRNI) mutant genotypes of 
Pfdhfr were detected in 4.7 % (2/43) isolates and 79.1 % (34/43), respectively.  
For Pfdhps, no single mutant genotype was detected in the isolates. Genotyping of 
P. falciparum isolates for the combined Pfdhfr– Pfdhps genes showed that one (2.3 
%), six (14 %), 22 (51.2 %), and 30 (69.8%) isolates had two, four, five and six 
mutant genotypes, respectively.  The quintuple mutant genotype 
(108/59/51/436/437) was significantly associated with women in the IPTp-SP arm 
(Table 4.12). 
Table 4.12: Proportion of combined mutated genotypes in both trial arms. 
 IPTp-SP arm 
N= 23 
ISTp-AL arm 
N=20 
Total p-value 
Mutated codons n % n % n (%)  
Pfdhfr-108 0 0 2 10 2 (4.7) 0.120 
Pfdhfr-108/59/51 18 78.3 16 80 34 (79.1) 0.891 
Combined Pfdhfr-Pfdhps 
genotypes 
      
108/437 1 4.3 0 0 1 (2.3) 0.348 
108/59/51/437 4 17.4 2 10 6 (14) 0.485 
108/59/51/436/437 18 78.3 4 20 22 (51.2) 0.0001 
108/59/51/436/437/581/613 18 78.3 12 60 30 (69.8) 0.192 
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5 DISCUSSION  
The research conducted in this thesis aimed to evaluate the effectiveness of 
intermittent screening and treatment with AL (ISTp-AL)for preventing malaria in 
pregnancy. The thesis also evaluated the baseline prevalence of parasite molecular 
markers of resistance to SP. This concluding chapter contains a summary and 
discussion of the major findings. It highlights the main recommendations and 
limitations of this work, considers possibilities for future work and outlines its 
implications for the broader context of malaria control. 
 
5.1 KEY FINDINGS 
This trial has shown that intermittent screening and treatment using artemether-
lumefantrine was not inferior to intermittent preventive treatment with sulfadoxine-
pyrimethamine in preventing severe maternal anaemia, the primary trial outcome. 
The trial was conducted in Calabar, South East Nigeria, a setting with perennial 
malaria transmission where P. falciparum is still sensitive to SP albeit at reduced 
levels and IPTp-SP is still likely to confer some protection against malaria in 
pregnancy. 
The overall prevalence of low birth weight was lower than the national average of 
15% (UNICEF, 2015). Babies born to women in the ISTp-AL treatment group were at 
a lower risk of being underweight at birth. Peripheral malaria parasitaemia at any 
time during pregnancy did not differ significantly between both treatment groups. 
However, there was a significantly higher risk of peripheral malaria parasitaemia in 
the IPTp-SP treatment group in the third trimester (36-40 weeks). Gametocytaemia 
detected by QT-NASBA was also very low, and no gametocytaemia was detected by 
microscopy. This is attributable to the low density of the malaria infections among the 
study participants. 
 
Among a subset of women in the ISTp-AL group who were RDT negative throughout 
pregnancy and did not receive any antimalarial treatment, the prevalence of third 
trimester severe anaemia and low birth weight was not significantly different from 
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women in the IPTp-SP treatment group. The incidence of preterm deliveries, 
abortions, and perinatal deaths was similar in both treatment groups.  
 
There was a high proportion of Pfdhfr and Pfdhps mutations among P. falciparum 
isolates from women involved in the study. The Pfdhfr triple mutation (codons 51, 59 
and 108) was detected in over 90% of P. falciparum isolates. No Pfdhfr mutations 
were observed at codon 164. Pfdhps mutations were detected in P. falciparum 
isolates at codons 436, 437, 581 and 613. No Pfdhps K540E mutation was observed 
among study women. The prevalence of triple Pfdhfr mutations was almost 80%. 
There was also a high prevalence of quintuple and septuple Pfdhfr-Pfdhps 
mutations. There was no significant difference in the distribution of mutant alleles 
between both treatment groups.  
 
5.2 LIMITATIONS OF THE RESULTS 
Limitations of the study include the lack of a complete set of observations for all 
women. Most of these women contributed data to the birth weight analysis, but about 
43% did not contribute data to third-trimester maternal anaemia which was the 
primary outcome. This loss of data is attributable to several national strikes 
embarked upon by different cadres of health workers that disrupted antenatal clinic 
attendance and adversely affected follow-up visits and the recording of related 
outcomes because the health facility was locked up over these periods.  With the 
exception of high level of data loss for the primary outcome, the overall rate of loss to 
follow-up rate was 8.5% and did not differ between the control and intervention 
group. Additionally, due to logistic constraints, we were unable to collect placental 
samples from all study women who had facility deliveries. The West Africa Ebola 
Epidemic in 2014 also adversely affected blood sample collection for molecular 
quantification of gametocytaemia by QT-NASBA. As Nigeria experienced a small 
outbreak, it was agreed with the supervisors to suspend the collection of blood 
samples for QT-NASBA as the analyses could not be carried out in Munich under the 
newly necessary security measures. 
Furthermore, the prevalence of malaria parasitaemia observed in this clinical trial 
was very low. This prevalence may have been underestimated due to the low 
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sensitivity of microscopy and RDTs. Perhaps, if a more sensitive method such as 
loop-mediated isothermal amplification (LAMP), with an estimated lower limit of 
detection 1-5 parasites per µl of blood (Oriero et al., 2015), was used, the prevalence 
might have been higher due to an identification of more sub microscopic 
parasitaemia. 
 
5.3 OVERALL INTERPRETATION 
The overall incidence of malaria and severe anaemia in study women was observed 
to be much lower than expected and relative to previously reported estimates from 
Nigeria (Olubukola et al., 2011, Nwizu et al., 2011, Agan et al., 2010). All the malaria 
infections among study women were mild, and none required hospital admission. 
Apart from the fact that pregnant women often have low-density asymptomatic 
malaria infections this finding may be explained by continued decline in the incidence 
of malaria cases and the sustained scale-up in coverage of preventive interventions, 
most especially LLINs. All study women received a LLIN at enrolment and were 
encouraged to continue sleeping under them at scheduled follow-up visits. The 
Cross River State government has also provided free medical care to pregnant 
women and under-fives since 2009. These may have also contributed to the low 
prevalence of malaria observed in the trial. 
The ISTp intervention was well received by most pregnant women and health 
providers in this study. This is similar to findings from a trial in West Africa (Smith et 
al., 2010). A few study women, however, withdrew consent from this study as a 
result of repeated blood draws and finger pricks. However, ISTp-AL is likely to be 
more expensive than IPTp-SP because of the cost of RDTs and doses of 
artemether-lumefantrine which are higher than the cost of a dose of SP. AL is also 
more complex to administer being a three-day treatment. Thus, adherence 
monitoring is more difficult and would mostly rely on self-report by pregnant women 
or home visits by health workers. From a programmatic perspective, to be able to 
deliver ISTp through antenatal clinics, health managers, and health policymakers will 
need to take into consideration the workload and changes in health provider 
responsibilities and issues around the sustainability of funding. 
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The transmission of parasites from humans to mosquitoes requires the presence of 
infectious gametocytes in the human peripheral blood. Consequently, pregnant 
women with asymptomatic parasitaemia could constitute a reservoir of parasites for 
the inoculation of mosquitoes (Kern et al., 2011). It is important to note that women 
in the IPTp-SP treatment group had a higher risk of parasitaemia compared to 
women in the ISTp-AL treatment group. AL has been shown to be more effective at 
reducing gametocyte carriage and malaria transmission to mosquitoes compared to 
DHA-P (Sawa et al., 2013).  ISTp with AL or other ACT regimens could reduce the 
incidence of malaria and anaemia which could bring immense health and 
socioeconomic benefits. These benefits could be considered to outweigh the lower 
cost-effectiveness of the approach in the long term. 
Previous trials (Tagbor et al., 2015, Tagbor et al., 2010, Gonzalez et al., 2014, Clerk 
et al., 2008, Kakuru et al., 2016) have investigated alternative drug regimens and 
strategies to replace SP for intermittent preventive treatment of malaria in 
pregnancy. The most promising results are from Western Kenya (Desai et al., 
2016).They found that IPTp with DHA-P was more effective than ISTp with DHA-P or 
IPTp with SP at preventing peripheral or placental malaria at delivery. This result 
suggests that ISTp as a strategy may not be suitable for settings with high 
transmission. A recently published trial (PREGACT Study Group, 2016) that 
evaluated four ACT combinations for the treatment of African pregnant women 
(second and third trimester) with malaria and found DHA-P to have the best efficacy 
and an acceptable safety profile. However, AL was associated with the fewest 
adverse effects and had an acceptable cure rate. 
 
Moreover, the sensitivity of RDTs currently in use suggest that available malaria 
RDTs may be inadequate for the screening of asymptomatic women who typically 
have low-density infection which is often missed by RDTs (Desai et al., 2016, Ahmed 
et al., 2015). There is also a concern about the absence of a prophylactic effect in 
women who test negative. This allows low-density infections to persist and increases 
the chance of new infections occurring between scheduled antenatal visits. 
More recently, there has been growing concern about reports of histidine-rich protein 
2/3 (pfhrp2/ pfhrp3) gene deletions. Most of the currently available RDT kits work by 
detecting histidine-rich protein II which is expressed only by P. falciparum. This 
preference was due to research findings that they are more sensitive and heat-stable 
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than RDTs that detect other malaria antigens, such as plasmodium lactate 
dehydrogenase (pLDH) or aldolase (World Health Organization, 2016a). 
 
Since 2010, when Gamboa and colleagues (Gamboa et al., 2010) reported the 
first confirmed identification of P. falciparum parasites with pfhrp2/pfhrp3 gene 
deletions there have been successive reports from Eritrea, Ghana, India, Mali and 
Senegal. This poses a serious public health challenge for parasitological 
confirmation of malaria as parasites with hrp2, or hrp3 gene deletions cannot be 
detected by HRP2-based rapid diagnostic tests (RDTs) resulting in false-negative 
results.  
There are other reasons for false-negative RDT results which still need to be 
taken into consideration such as poor transport and storage conditions of RDTs, 
sustained exposure to high temperature as well as host-parasite density. There is 
also the chance of human error in performing or interpreting the test result. Thick 
or thin films may also be incorrectly interpreted as positive by microscopy. 
Continued human capacity building for microscopist is required to ensure results 
from microscopy represent a reliable gold standard against which RDT results can 
be compared. NMCPs may also procure alternative RDTs such as the SD Bioline 
Malaria Ag P.f (HRP2/pLDH) test kits used in this trial, which do not rely 
exclusively on HRP2 for P. falciparum detection. 
WHO recently recommended the continued use of IPTp-SP for the prevention of MiP 
as there is not sufficient evidence to suggest that it be replaced by ISTp or any other 
drug regimen replacing SP for use as IPTp. The WHO also recommends that 
National Malaria Control Programmes (NMCP) consider discontinuing IPTp-SP when 
the population prevalence of P. falciparum dhps mutation K540E is greater than 
95%, and the prevalence of mutation A581G exceeds 10 %, as it is likely to be 
ineffective (World Health Organization 2016b).  
 
In this study, among pregnant women, before the commencement of IPTp-SP, the 
Pfdhfr mutations 51I, 59R and 108N were almost fixed with all three mutations being 
present in more than 70% of the isolates. There was no I164L mutation in the study 
samples a finding similar to a previous study in Nigeria (Happi et al., 2005). 
However, the frequency of the triple Pfdhfr mutation was also high (70%). The Pfdhfr 
triple mutation is known to confer intense pyrimethamine resistance in vitro (Gregson 
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and Plowe, 2005).  The Pfdhfr mutations are known to have emerged about a 
decade or two before the Pfdhps double mutant genotype in Africa (Talisuna et al., 
2004) and are now well established across sub-Saharan Africa.  The high level of 
triple Pfdhfr mutations found in this study could be explained in part by the fact that 
pyrimethamine was previously used as weekly chemoprophylaxis to prevent malaria 
in pregnancy (Fawole and Onyeaso, 2008, Yusuf et al., 2008). Also, cotrimoxazole 
use has been associated with the emergence, spread and intensification of the 
A437G and K540E mutations in the Pfdhps gene (Gesase et al., 2009). In Nigeria, 
there is a high burden of pneumonia and cotrimoxazole is commonly used as 
prophylaxis or treatment among HIV patients and children with pneumonia 
(Onyedum and Chukwuka, 2011). 
In the Pfdhps gene, the frequency of the core mutation, A437G, was over 90%. 
Although the K540E mutation is very frequently found in association with the A437G 
mutation (Pearce et al., 2009, Kublin et al., 2002), the K540E mutation was absent 
from all the P. falciparum isolates in this study. Thus, there was no Pfdhps double 
mutation, at codon 437 and 540 which is a predictor of post-treatment SP resistance 
(Kublin et al., 2002, Plowe et al., 2004).  Although Pfdhfr/dhps quintuple mutants are 
rare in West Africa, recent studies have reported the emergence of the K540E 
mutation. This mutation is known to be a reliable marker for parasites carrying the 
quintuple mutants. Studies from the western part of Nigeria have found an 
emergence of mutant P. falciparum isolates carrying sulfadoxine resistance 
associated A437G and K540E mutations in the Pfdhps gene (Iwalokun et al., 2015, 
Olasehinde et al., 2014, Happi et al., 2005).  
However, the occurrence of A437G combined with A581G mutation confers higher 
levels of SP resistance (Pearce et al., 2009), and this combination of A581G/A437G 
mutations was present in twenty of twenty-eight isolates. The prevalence of the 
S436A mutation, which is an additional mutation that follows the emergence of 
A437G mutation was over 80%. This additional mutation corresponds to an increase 
in the degree of resistance to SP.  
The combination of A437G mutation with the Pfdhfr triple mutation (51I/59R/108N) is 
considered to be associated with SP treatment failure (Mockenhaupt et al., 2005) 
and was detected in over 70% of the isolates.  
86 
 
The prevalence of the triple Pfdhfr and A437G/A581G Pfdhps mutations were very 
high; suggesting that the efficacy of SP as IPTp in Southeast Nigeria may be 
severely threatened. However, the K540E mutation was absent suggesting that SP 
may still be efficacious when used as IPTp.  
 
ISTp remains a valuable approach to the control of MiP that needs to be further 
explored. IST may have other malaria control applications in endemic countries as 
they approach pre-elimination phase of malaria control, characterised by low-density 
infections in asymptomatic carriers. The intermittent screening may serve as a 
malaria surveillance tool for monitoring malaria levels in the population. Active 
detection of malaria infection has been demonstrated to have an impact on 
miscarriage and preterm delivery (Bardaji et al., 2011). ISTp may also be 
recommended in the first trimester of pregnancy when IPTp-SP is not recommended 
or restricted to the first ANC visit. Screening at initial ANC visit has been shown to 
detect up to 50% of all the malaria infections diagnosed throughout the course of 
pregnancy (Williams et al., 2016). 
Furthermore, combining IPTp-SP and ISTp may result in lower fitness of SP-
resistant parasites as there may be a fitness cost of the Pfdhfr and Pfdhps mutant 
haplotypes in the absence of a strong SP pressure (Zhou et al., 2008, Bacon et al., 
2009). 
. 
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6 CONCLUSION  
Malaria is a major parasitic disease in sub-Saharan Africa and remains a major 
public health issue. Despite reported global decline in clinical cases of malaria and 
malaria deaths including in Africa  pregnant women and children aged less than five 
years are remain particularly vulnerable to clinical disease when the get infected. 
Intermittent preventive treatment (IPTp) with SP along with use of ITNs for vector 
control and prompt access to diagnosis and treatment of clinical malaria with ACTs 
are the key interventions currently recommended by WHO for the control of malaria 
in pregnancy. 
However, there is widespread and established parasite resistance to SP in the 
Southern and Eastern parts of Africa. Reports indicate the emergence of SP 
resistance in West African countries too. Despite widespread parasite resistance to 
SP in Southern and Eastern Africa, SP remains the drug of choice for intermittent 
preventive treatment of malaria in pregnancy in West Africa. However, there have 
been increasing reports of emerging SP resistance even in West Africa. This 
emerging SP resistance calls to question the effectiveness of SP as a preventive 
intervention for malaria in pregnancy.  
It has been argued that the continued use of SP for intermittent preventive treatment 
in pregnant women, may further increase the prevalence of SP-resistant parasites 
and lead to the selection of new mutations. It may be better to administer full malaria 
treatment doses to pregnant women only when they have parasitaemia as a 
mechanism for reducing drug pressure and resistance. 
As part of my PhD program, we undertook to investigate a different approach to 
preventing malaria in pregnancy. We conducted a clinical trial from October 2013 to 
November 2014. We designed a non-inferiority clinical trial described in chapter 3 to 
determine whether providing LLIN plus RDT screening and treatment (ISTp) is non-
inferior to LLIN plus IPTp-SP in reducing the burden of malaria during pregnancy. 
The primary outcome of the trial was the prevalence of severe maternal anaemia 
(Hb<8g/dl) in the third trimester. We also determined the prevalence and density of 
gametocytaemia and parasitaemia at each visit. Other secondary endpoints included 
the prevalence of low birth weight, moderate anaemia (Hb < 11g/dl), placental 
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malaria, and the incidence of spontaneous abortions, intrauterine deaths/stillbirths, 
neonatal and maternal mortality, and developmental delays. A sub-study of the 
thesis was the determination of the prevalence of molecular markers of parasite 
resistance to SP among the pregnant women.  
A total of 459 pregnant women were randomly assigned to receive either ISTp-AL or 
IPTp-SP. The study took place in the ANC clinic of the General Hospital in Calabar, 
the capital city of Cross River State in South eastern Nigeria. The interventions were 
given during the second and third trimesters with primary outcome evaluation at 36-
40 weeks gestation. 
The main results were reported in Chapter 4. ISTp-AL was non-inferior to IPTp-SP in 
preventing third-trimester maternal anaemia (RD -1.75% [-4.16% to 0.66%]) 
according to the non-inferiority margin of 5% set a priori. However, the results 
obtained for third-trimester anaemia are likely not powered to exclude small clinically 
significant differences based on the sample size calculation, and non-inferiority 
margin set a priori. However, the According-to-protocol (ATP) and modified intention-
to-treat (mITT) analyses yielded similar results and loss to follow-up was 8.5%, and 
there was no significant difference in numbers of women lost to follow-up between 
the treatment arms. 
 The prevalence of moderate anaemia was lower in the ISTp-AL group but not 
significantly different from the IPTp-SP group. The risk of LBW was significantly 
lower in the ISTp-AL group in an adjusted analysis. Similarly, the risk of maternal 
malaria parasitaemia in the third trimester was significantly lower in the ISTp-AL 
group. Placental malaria was rarely found among the few samples obtained from 
study women. Gametocytaemia was not different between both study groups 
although the trial was not powered to detect small difference in gametocytaemia. The 
incidence of abortions, perinatal deaths and pre-term deliveries were comparable in 
both study groups. Other relevant findings of this trial were the high prevalence of 
the Pfdhfr triple mutation (51I59R108N). In the Pfdhps gene, the prevalence of the 
436A, 437G, 581G and 613S mutations was also high. 
ISTp as an approach to control malaria in pregnancy may be more effective when 
highly sensitive RDTs become available and if treatment can be with a single dose 
regimen, preferably produced from non-artemisinin derivatives, but effective against 
gametocytes. This will ensure therapy can be directly observed at the antenatal 
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clinic. The use of a non-artemisinin-based drug would prevent the potential 
development and spread of artemisinin resistance in sub- Saharan Africa.   
 
This study showed non-inferiority of ISTp-AL to IPTp-SP for preventing maternal 
anaemia in pregnant women in an area of high malaria transmission and moderate 
SP resistance. ISTp remains one of the potential alternatives to IPTp-SP, and its 
relevance will become more evident when the sensitivity of current generation of 
RDTs are improved beyond present levels.  In the meantime, high priority must be 
given to identifying safe and cost-effective alternatives to SP for use in IPTp.  There 
is also need to ensure access for pregnant women to long-lasting insecticide-treated 
nets and prompt diagnosis and effective treatment. 
6.1 AREAS FOR FUTURE RESEARCH 
This thesis has explored an alternative strategy for preventing malaria in pregnancy. 
However, several research questions remain and call for further investigation. 
Currently available rapid diagnostic tests cannot detect either the low-level blood-
stage infections of any malaria species or the dormant liver stages of P. ovale and P. 
vivax. A highly sensitive point-of-care field test is needed to detect low-density 
parasitaemia rapidly and identify all infected individuals, enabling immediate 
treatment (Hemingway et al., 2016). Research in this respect is required and will 
determine the level of success that can be achieved with reducing the infectious 
burden of malaria. 
Future research is also required to confirm and map HRP2/HRP3-deleted parasites 
across sub-Saharan Africa. There is also need to identify ways of improving the 
performance of pLDH based tests as well as identify new target antigens for use in 
RDTs. 
While screening for Pfdhps K540E, a predictor of the quintuple mutant should remain 
a priority in Nigeria and West Africa, research to evaluate the threshold of SP 
resistance above which IPTp-SP is no longer effective would also be useful. Also, 
the evaluation of alternative preventive treatment options for preventing malaria in 
pregnancy should be a priority. It may be worthwhile to evaluate the preference of 
pregnant women between a community-based and a facility-based approach to 
ISTp. 
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ISTp may be more appropriate for chemoprevention in HIV-infected women for 
whom SP use is contraindicated because of concomitant prophylaxis with 
cotrimoxazole. Clinical trials are required to evaluate the potential benefits and 
harms of ISTp in this peculiar group of pregnant women. 
. 
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